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ABSTRACT 
 
Antimicrobial peptides (AMPs) and photosensitizers (PS) have gained attention 
as potential alternatives to traditional antibiotics for the treatment of microbial infection 
due to the decreased likelihood for acquired resistance. However, many AMPs and PS 
suffer from insufficient activity, specificity, or a combination thereof. AMPs can require 
high concentrations for effective activity, leading to non-specific side effects and 
increased costs. PS, on the other hand, are quite active, but are typically hydrophobic 
and suffer from non-specific binding and damage to host tissues. To solve these 
problems, we report a novel PS-AMP construct of the soluble PS eosin Y conjugated to 
the selective AMP (KLAKLAK)2. Eosin Y has a high singlet oxygen quantum yield, 
which is suitable for photodynamic activity, although the solubility of eosin Y results in 
poor binding and activity toward membranes on its own. On the other hand, the 
specificity of (KLAKLAK)2 is high for an AMP, but could still benefit from enhanced 
activity at lower concentrations. The killing activity and binding specificity of eosin-
(KLAKLAK)2 toward both bacteria and mammalian cells was assessed using 
microbiology, biochemistry, and fluorescence microscopy techniques. Additionally, the 
mechanism of eosin-(KLAKLAK)2 activity was investigated using liposome models to 
determine factors involved in binding and membrane disruption. Furthermore, novel 
applications of transmission electron microscopy (TEM) methods were employed to 
observe the photodynamic effects of eosin-(KLAKLAK)2 against bacteria.  
 iii 
 
The PS-AMP conjugate eosin-(KLAKLAK)2 displays synergistic activity 
between PS and AMP in model liposome systems, and is capable of killing several 
clinically relevant bacteria, including the multi-drug resistant Acinetobacter baumannii 
AYE strain. Furthermore, bacterial killing is achieved in the presence of red blood cells 
(RBCs) and other mammalian cell lines without significant toxicity. Liposome models 
reveal that the lipid composition of bacteria is a potential factor responsible for the 
observed binding specificity and corresponding activity. Additionally, TEM methods 
show that eosin-(KLAKLAK)2 causes extensive membrane damage to both Gram 
positive Staph aureus and Gram negative Escherichia coli, indicating a primary cause of 
cell death. A model is proposed where the activities of the PS and AMP, respectively, 
facilitate the activity of one another, leading to enhanced membrane disruption, and 
effective antibacterial activity while maintaining cell selectivity. 
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NOMENCLATURE 
 
PS photosensitizer(s) 
ROS reactive oxygen species 
UV ultra-violet 
VIS visible 
IR infrared 
(a)PDT (antimicrobial) photodynamic therapy 
PDI photodynamic inactivation 
PEI polyethyleneimine 
(A-)AMP(s) (amphipathic)-antimicrobial peptide(s)  
RBC(s) red blood cell(s) 
FDA Food and Drug Administration 
EM electron microscopy 
(S)TEM (scanning) transmission electron microscopy 
EDS electron dispersive x-ray spectroscopy 
DAB 3,3,-diaminobenzidine 
Ce6 chlorin e6 
MB methylene blue 
HaCaT human keratinocyte cell line 
COLO-316 human ovarian carcinoma 
COS-7 African green monkey kidney cells 
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TAT transactivator of transcription peptide 
ATCC American Tissue Culture Collection 
FWHM full width, half maximum 
EMCCD electron multiplying charge coupled device 
DMEM Dulbecco’s Modified Eagle Medium 
RNO p-nitrosodimethylaniline 
NBT nitro blue tetrazolium 
LUV large unilamellar vesicle 
PC 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine 
Chol cholesterol 
SM choline sphingomyelin 
PE phosphatidyl ethanolamine 
PG phosphatidyl glycerol 
CA cardiolipin 
MIC minimum inhibitory concentration 
RI retro inverso 
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1. INTRODUCTION 
 
1.1 History and description of photosensitizers 
Photosensitizers (PS) are dyes that are typically non-toxic in the dark, but upon 
light excitation, can react with oxygen in the local environment to form reactive oxygen 
species (ROS). The production of ROS can lead to the damage of biological molecules 
including proteins, lipids, and nucleic acids. This has led to the study of PS for various 
therapeutic applications.
1
 Although the damaging effects of ROS have potential for 
therapeutic use, there are significant concerns related to non-specific damage.
2
 Methods 
to enhance PS specificity would thus be a valuable improvement for therapeutic 
applications or for studying biochemical responses to acute ROS production. 
The earliest observation that photodynamic action required light, oxygen, and a 
photosensitizing molecule was made by Downes and Blunt in 1877, who saw that 
bacterial growth was prevented in certain solutions only when exposed to both light and 
air.
3
 However, the broadly used term in the field, “photodynamische wirkung” (loosely 
translated “photodynamic activity”) was not coined until 1900 when H. von Tappeiner’s 
student, Oscar Raab, mixed the fluorescent dye acridine orange with bacteria that 
subsequently died in the presence of light and oxygen.
4
 Another early discovery of note 
came from Friedrich Meyer-Betz in 1913, who self-administered a dose of 
hematoporphyrin, an acid hydrolysis product of hemoglobin. After exposure to sunlight 
for ten minutes, an inflammatory response occurred in his skin followed by pealing, with 
photosensitivity remaining for weeks afterward.
5, 6
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Over a century after these early discoveries, there is an extensive list of 
characterized PS, with a variety of maximum excitation wavelengths ranging across the 
ultraviolet (UV), visible (VIS),  and near infrared (IR) spectrum.
7
 The excitation 
wavelength may be particularly important for certain applications. For example, a PS 
excited by IR is generally preferable for achieving a certain degree of tissue penetration.
8
 
However, PS with excitation wavelengths in the visible range may be more convenient 
to monitor in laboratory assays, and for use with more traditional light sources.
9,10
 
Structurally, PS are generally composed of conjugated ring systems that are 
typical of light-absorbing and fluorescent molecules.
11
 Some common fluorophores also 
have an appreciable photosensitizing activity, although they may not be typically used as 
PS.
7
 Common antimicrobial PS include porphyrins, chlorins, pthalocyanines, xanthenes, 
or phenothiazines.
1
 Depending on the atoms inherent to the PS structure, charged groups 
are often added to aid solubility in aqueous solutions.
12
 Their photodynamic activity also 
typically correlates with their lipophilicity and effective photosensitizers often have a 
high propensity to bind and damage biological membranes.
13, 14
Hydrophobicity, 
however, can have both beneficial and negative impacts upon the photodynamic activity 
of a PS.
15,16
 Hydrophobicity can lead to aggregation and a decreased PS availability for 
binding to intended targets. Another common structural modification is halogenation, 
found commonly with fluorescein-based PS derivatives. Halogenation typically results 
in a greater triplet state quantum yield for these structures, thus enhancing the 
photodynamic activity.
7
 Halogenation also conveys protection to the PS against damage 
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caused by the ROS that the PS itself produces. Protection from the ROS will then 
increase the useful lifetime of the molecule in the context of its photodynamic activity.
17
 
 
1.1.1 Development of photosensitizers as antimicrobial agents 
The general use of PS for therapeutic purposes has been broadly termed 
photodynamic therapy (PDT), although this particular term is most often associated with 
the killing of cancer cells.
11
 Applications of PS range from targeted killing of cancer 
cells, to dermatological treatments (e.g. acne
1, 18-20
 and psoriasis
21, 22
), to antifungal
8, 23, 24
 
and antibacterial treatments (e.g. blood decontamination
25-27
 and oral infection
28
). The 
use of PS for the specific application of killing bacteria or other microbes is called either 
antibacterial or antimicrobial PDT (aPDT), or alternatively, photodynamic inactivation 
(PDI). One of the most promising signs for PDI is the observation that attempts by some 
groups to promote an acquired bacterial resistance to PDI in the laboratory using 
repeated sub-lethal treatments, have failed to produce resistant strains.
29
 This approach 
also appears to kill antibiotic resistant strains as effectively as their antibiotic sensitive 
counterparts.
30,31
 
In order to promote targeting of PS to bacteria, modifications have been made to 
the structures of PS, generally increasing positive charge, to promote attraction to the 
negatively charged surface of bacterial membranes. This approach has had some success 
using addition of amino group substituents, or attachment of the PS to poly-lysine 
chains, or certain positively charged peptides.
32-34
 The photodynamic efficacy of PS 
towards Gram-negative bacteria has been improved by addition of cationic compounds 
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such as poly-lysines and poly-ethyleneimine (PEI).
35-37
 The size of the polymer 
conjugate is an important determinant of the efficacy with which bacterial 
photoinactivation is achieved.
12
 For instance, Escherichia coli was not photo-inactivated 
efficiently by a PS conjugated to small molecular weight pL (i.e. 8 lysines).
12
 However, 
a larger pL conjugate (i.e. 37 lysines) was more phototoxic, presumably because of the 
increased propensity of the large polycationic compound to disrupt the outer membrane 
of Gram-negative bacteria.
38
 On the other hand, large pL complexes might not permeate 
the surface layer of Gram-positive bacteria as efficiently as smaller analogs because of a 
molecular-sieving effect.
12, 39
 Consequently, increasing the size of a pL-PS conjugate 
might increase activity against Gram-negative bacteria but reduce the photoinactivation 
efficiency achieved against Gram-positive strains. As one might expect, modifications 
such as these are especially helpful for those PS with low inherent solubility.
40
 Another 
approach to circumvent the hydrophobicity of some PS has been to use liposome or 
micelle delivery platforms.
41, 42
 While these approaches have had some success, some 
considerable hurdles still exist for PDI.  
 
1.1.2 Proposed mechanisms of PS in antimicrobial applications 
The mechanism for the photodynamic activity of PS is well understood today. A 
PS undergoes a process resembling phosphorescence, where absorption of light leads to 
transition of an electron from its ground state (S0) to an excited state (S1), followed by 
intersystem crossing to the triplet state (T1). Instead of phosphorescing, however, a PS 
achieves photodynamic activity through one of two competing pathways originating in 
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the triplet state. A PS can either react: 1) in an electron transfer mechanism with 
molecular oxygen (O2), other substrates, or solvent, or 2) in an energy transfer 
mechanism with molecular oxygen.  
The classification of these PS reactions are not always consistent in the 
literature.
6,43,44
 For this work, I will use the most commonly used definition in the PS 
field.
45
 According to this classification, a Type I photosensitizing mechanism involves 
electron transfer via hydrogen atom or lone electron. Examples of Type I reactions 
include: 1) the formation of superoxide (O2∙
-
) by electron transfer from a PS, or 2) lipid 
radical formation after removal of a hydrogen atom by the PS. A Type II mechanism is 
defined by resonant energy transfer from the excited PS to ground state molecular 
oxygen (triplet state, 
3
O2), resulting in the formation of an excited state singlet oxygen 
(
1
O2). This last process is unique in that the ROS produced is an excited state molecule 
which can decay to its ground state without necessarily undergoing a secondary reaction 
with other substrates. This characteristic may impart a greater degree of spatial 
restriction to the activity of singlet oxygen. Conversely, other ROS (O2∙
-, HO∙, and 
H2O2) persist in their chemical states until they react with another molecule.
46
  
The ROS produced can result in a network of damaging reactions to biological 
molecules, such as lipids, proteins, and nucleic acids. In the lipid membrane, ROS can 
produce lipid hydroperoxides (LOOH), which can lead to subsequent rounds of radical 
lipid peroxidation.
47
 Low levels of ROS-mediated lipid damage may be tolerable, but 
sufficient damage can lead to irreparable damage and cell death.
48
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1.1.3 Present problems with PS treatments 
Achieving specific targeting may be the single greatest problem facing the use of 
PS in therapeutic applications.
1
 When trying to target cancer cells, bacteria, or fungi for 
in vivo PDI, non-specific damage to healthy cells can occur with detrimental effects. For 
example, earlier attempts in mouse models to accelerate wound healing after bacterial 
infection using a porphyrin derivative, actually delayed healing compared to mice not 
treated with PDI, since the skin was injured by the treatment
49
 This result may not be 
that surprising, considering the affinity that porphyrins typically have for mammalian 
tissue, exemplified by the persistence of sensitization from porphyrins in patients.
6
 
Recently, however, some notable successes for topical infections in mice have been 
demonstrated with the fullerene BF6 and the phthalocyanine derivative RLP068.
40, 50
 
Hamblin and co-workers have shown that the binding of pL-PS conjugates to microbial 
cells is very rapid while the endocytic uptake of these compounds into human cells is 
slower.
12, 37, 51
 In principle, it is therefore possible to target and kill bacteria selectively 
by controlling the time cells are exposed to the conjugates. However, moieties that can 
target bacteria while inducing minimum endocytic uptake in human cells might provide 
a better selectivity between these different cell types and be more practical in general. 
Another inherent limitation to PS treatments is the requirement of light. 
Penetration of visible light into tissue is generally on the order of 1 mm, while near 
infrared (e.g. 750 nm) may penetrate up to 10 mm.
52
 This prevents the use of PS in more 
internal locations unless the region can be surgically accessed, which can be undesirably 
invasive. The other side of this problem, as exemplified by porphyrins again, is not being 
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able to turn the light off (or go out in the sun), requiring patients to carefully cover their 
skin.  
While acquired resistance to PDI has not been seen, Gram negative bacteria 
appear to have a naturally increased resistance to PDI treatments compared to Gram 
positive counterparts. Higher concentrations of PS or light dose are usually required to 
kill Gram negative strains to the same extent as Gram positive strains. These effects are 
likely due to the additional physical barrier presented by their outer membrane, and the 
additional targets in the outer membrane that can prevent ROS reaching the cell 
membrane or cellular interior.
53
 
 
1.2 History of antimicrobial peptides (AMPs) 
The antimicrobial peptide (AMP) magainin, was first discovered in the African 
clawed frog Xenopus laevis, when surgical incisions repeatedly failed to produce 
infection, even though the frogs were placed back into non-sterile water after stitching 
the incisions.
54
 Extracts of the skin revealed that two peptides (magainin 1 & 2) with 
closely related sequences were responsible for the antimicrobial activity. This discovery 
opened up the field to a vast number of peptides with analogous function, along with the 
realization that these peptides were a part of the innate immune system of all 
multicellular organisms.
55
 The assortment of AMPs discovered generally fall into a few 
conserved structural classes, including helical, β-sheet, and extended structures.56  
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1.2.1 Development of AMPs as antimicrobial agents 
Regardless of class, AMPs are most often characterized by positive and 
hydrophobic residues, providing for electrostatic attraction to the negatively charged 
surface of bacteria, and an affinity for the lipid membrane. Association of AMPs with 
the membranes of bacteria leads to membrane disruption, leakage, and cell death. This 
activity has brought much attention to AMPs as potential therapeutic agents for 
antibiotic-resistant bacteria.
57
 The therapeutic potential for AMPs was particularly 
supported by a report in 2006, which demonstrated the requirement of 600-700 bacteria 
culture passages before resistance was noted.
58
 The first clinical trial for an AMP was 
with a modified analog of the original Magainin peptide, which showed comparable 
activity to a traditional antibiotic in the treatment of foot ulcers. However, the Food and 
Drug Administration (FDA) did not approve the treatment because of its lack of 
improvement over existing therapies.
57, 59, 60
 To date, there are still no AMPs approved 
for therapeutic use, although several AMPs and synthetic structural analogs are in 
clinical development.
57, 61
 An increased understanding of the mechanisms involved in 
membrane disruption may allow for sufficient improvements in design for such peptides 
to become therapeutics in the near future. 
1.2.2 Proposed mechanisms of AMPs in antimicrobial applications 
To complement the negative surface charge of bacteria, most AMPs are 
positively charged and electrostatically attracted to the bacterial surface. Cellular targets 
include lipid A in Gram negative bacteria, the peptidoglycan layer of Gram positive  
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Figure 1-1 Models of membrane disruption by AMPs. Carpet (a), toroidal pore (b), 
and barrel stave (c) models. Used by permission.
62
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bacteria, negatively charged phospholipids, and even intracellular targets for some 
AMPs.
63, 64
 There are differing and disputed mechanisms for different AMPs, which 
generally consist of a membrane disrupting activity.
56, 65
 Helical amphipathic AMPs (A-
AMPs) are the most frequently modeled in the literature, typically using model liposome 
systems. A-AMPs are easily synthesized, and are not dependent on disulfide chemistry 
like certain AMP classes, making A-AMPs easier to handle.  
The most common membrane disruption models are depicted in Figure 1, which 
include the toroidal pore, barrel stave, and carpet models. Each of these mechanisms 
relies upon a threshold concentration of AMP bound to the membrane before stable pore 
formation can take place.
62
 Using liposome models, an early binding phase is observed 
with membrane thinning increasing with AMP concentration. A threshold is then 
reached where pore formation occurs, with the membrane width remaining constant 
thereafter.
66
 In the context of PDI, such pore formation is toxic to the bacteria. 
Therefore, understanding the chemical properties and structural features required to 
enhance this activity, while also maintaining sufficient specificity to bacterial 
membranes, is of great importance to the field. 
 
1.2.3 Potential problems of AMP-based treatments 
To achieve bacterial killing, a high concentration of AMPs can be required for 
sufficient activity, leading to undesirable non-specific side effects.
65
 The membrane 
disruption activity of AMPs is also thought by some to be equally disruptive to 
mammalian cells under the conditions where the same amount of peptide is bound. 
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However, these conditions are usually avoided due to a more favorable attraction to 
bacterial cells.
65
 Improvements to cell specificity with synthetic mimics could decrease 
side effects and lower the costs of treatment, making synthetic AMP mimics an area of 
increasing interest.
61
 
A major concern for the use of AMPs as therapeutic agents has been the evidence 
for resistance mechanisms in several bacteria strains against AMP activity. These 
mechanisms include charge modification of Lipid A and cell membrane phospholipids, 
efflux pumps for peptide export, peptidase activity, modification of intracellular targets, 
and DNA mutations among others.
63
 If AMPs are to become legitimate therapeutic 
treatments, it will be necessary to recognized resistance mechanisms over time and 
continue to develop AMPs or mimics with improved activity. 
 
1.3 The use of PS-peptide conjugates: current successes and shortfalls 
Within only the last year, two groups have published on conjugates of porphyrin 
derivatives with AMPs as targeting agents, one of which was submitted during the same 
time as our own work described herein.
67, 68
 The first was an AMP with specific affinity 
for LPS, using protoporphyrin IX as a PS.
67
 This work demonstrated successful killing 
of four Gram negative strains, with preferential binding to bacteria over Jurkat cells. 
While this construct was effective, it is presumably limited to use on Gram negative 
bacteria. Since PDI treatments are likely to require killing of both Gram negative and 
positive bacteria, a compound with activity against both Gram types is preferable. The 
second work mentioned above used the AMP Apidaecin 1b (from the honey bee), also 
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with a porphyrin derivative attached.
68
 Apidaecin 1b does not disrupt bacterial 
membranes, but instead achieves its antimicrobial activity by binding intracellular 
targets. For that construct then, it serves only as a targeting agent. This construct was 
able to kill Gram negative E. coli, although killing of the Gram positive S. aureus was 
limited even at relatively high concentrations around 15 µM. 
Apart from AMPs, other peptides have been used to target PS to bacteria. One 
group conjugated the arginine-rich cell-penetrating peptide TAT to the porphyrin 
derivative, TPP.
33
 While this construct was shown to kill both Gram positive and Gram 
negative bacteria in vitro, bacteria killing experiments were not performed in the 
presence of other cell types, nor was the conjugate tested for hemolytic activity towards 
RBCs. TAT has been shown to have extensive endocytic uptake by mammalian cells, so 
one could envision that the specificity for the TAT-TPP construct is likely non-existent, 
or even biased towards targeting of mammalian cells. Furthermore, conjugation of TAT 
to the otherwise innocuous fluorophore, tetramethylrhodamine, has been shown to be 
highly toxic to mammalian cells, as TAT places TMR in sufficient proximity to 
membrane targets to cause extensive membrane blebbing and cell death.
69
 Although the 
TAT-TPP conjugate might conceivably be used outside the body, these two works assert 
the caution that must be taken when choosing a method to target PS to bacteria, as well 
as the extent of testing that should be performed to determine the suitability for certain 
antibacterial applications. 
A general concern for the conjugation of a PS to a targeting agent is that certain 
photosensitizers have poor solubility, such as hematoporphyrin. PS with low solubility 
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can lead to non-specific retention of the free PS in tissues, and lengthened patient 
sensitivity to light. One can envision then, that the use of an AMP to target a 
hydrophobic PS might be successful initially, but if the AMP were to be degraded by 
proteases, then the free PS might create problems similar to those with hematoporphyrin. 
Additionally, and perhaps more importantly, the hydrophobic nature of a PS conjugated 
to the AMP might significantly reduce the binding specificity of the peptide, making the 
treatment less effective overall. 
 
1.4 A possible solution for increasing specificity and activity of PS: targeting a 
soluble PS by conjugation to a selective AMP 
One approach to achieve broad spectrum bacterial killing (both Gram positive 
and negative) while sparing other cells, might be to choose an AMP as a PS-targeting 
agent, which has demonstrated such bacteria killing and selectivity on its own. One 
example of such an AMP is (KLAKLAK)2, which shows similar killing towards both E. 
coli and S. aureus, while having low red blood cell lysis and low toxicity to mammalian 
cells.
70
 This type of targeting agent could potentially participate in the membrane 
disruption process during PDI, since the peptide itself has membrane lytic properties. If 
the AMP could participate in the membrane lysis event, this might lead to a bacteria 
killing efficiency greater than the sum of the two entities alone. 
The choice of a PS with high solubility could also be advantageous, since the PS 
would not be expected to interfere with the targeting and membrane interaction of the 
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AMP. Furthermore, if the AMP were to be degraded, the soluble PS would not bind to 
cells on its own, and might simply be eliminated from the body.  
 
1.5 The goal of my study 
Although both PS and AMPs have found some successful applications, there are 
significant limitations for their therapeutic use, due to either non-specific effects or the 
requirement for unreasonably high concentrations. A recent development has 
successfully targeted a PS to Gram negative bacteria,
67
 however, to our knowledge, an 
agent for broad spectrum targeting of PS to bacteria has not been established prior to 
separate works of another group
68
 and our own.
10
 We reasoned that the broad spectrum 
activity of the model AMP (KLAKLAK)2 might convey broad spectrum targeting for a 
soluble PS if it were conjugated to the AMP. To this end, I used the PS-AMP conjugate 
eosin-(KLAKLAK)2 to study the general principle of targeting a PS to bacteria using an 
AMP. I tested this hypothesis and studied the mechanisms of the conjugate activity using 
both in vitro and in cellulo approaches. This work serves as a proof of concept and lays 
the groundwork for the rational design of photosensitizing compounds with greater 
efficiency and targeting specificity.  
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2. EOSIN-(KLAKLAK)2 IS AN EFFICIENT ANTIBACTERIAL AGENT WITH 
HIGH SPECIFICITY FOR A BROAD SPECTRUM OF BACTERIA
*
 
 
2.1 Introduction 
In this section I tested whether an amphiphilic antimicrobial peptide (A-AMP) 
might serve as an attractive tool to target PS to bacterial membranes.
71
 While A-AMPs 
are typically cationic, they nonetheless contain fewer positive charges than poly-lysine 
or CPPs. Consequently, their endocytic uptake into mammalian cells is expected to be 
comparatively reduced. Overall, our hypothesis was therefore that an A-AMP would 
improve the antimicrobial photodynamic effect of a PS while inducing little damage 
toward mammalian cells. 
To test this hypothesis, a conjugate between the antimicrobial peptide 
(KLAKLAK)2 and the photosensitizer eosin Y was used (eosin-(KLAKLAK)2).
70, 72
 On 
one hand, (KLAKLAK)2 is a prototypical A-AMP with minimum inhibitory 
concentration (MIC) values of approximately 6 M for E. coli, P. aeruginosa, and S. 
aureus.
70, 73
 Moreover, hemolytic concentrations and sublethal concentrations to 3T3 
cells are two orders of magnitude greater than MIC values.
70
 On the other hand, eosin Y 
is a photosensitizer that, despite a high quantum yield of singlet oxygen (Φ~0.6), is not 
very phototoxic on its own.
13
 This can be attributed in part to the fact that eosin Y is 
                                                 
*
 Reprinted with permission from “Photoinactivation of Gram positive and Gram negative bacteria with 
the antimicrobial peptide (KLAKLAK)2 conjugated to the hydrophilic photosensitizer eosin Y” by 
Johnson, G.A., Muthukrishnan, N., Pellois, J.P., 2013. Bioconjugate Chemistry, 24, 114-123, Copyright 
2013 American Chemical Society. 
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relatively hydrophilic and that it does not significantly partition into membranes.
13
 We 
were therefore interested in testing whether (KLAKLAK)2 could enhance the 
photodynamic activity of this singlet oxygen generator by bringing it in proximity to 
bacterial membranes. The choice of a PS with low intrinsic phototoxicity might seem 
surprising as a starting point. However, we were concerned that a more photoactive but 
more lipophilic PS might significantly compromise the targeting specificity of the A-
AMP conjugate. Indeed, many PS are too lipophilic to distinguish between human and 
bacterial bilayers. With eosin-(KLAKLAK)2 however, we anticipated that the A-AMP 
would dictate binding specificity with minimal interference by the conjugated PS. 
 
2.2 Results 
2.2.1 Design of a light irradiation apparatus for high throughput of 
photosensitizing samples 
In order to efficiently process light-irradiated samples in a 96-well plate, we 
designed an apparatus that could provide an even distribution of light over all wells, 
depicted in Figure 2-1. This design consisted of an inexpensive 600 W halogen lamp 
(Utilitech #0320777) purchased from a local hardware store. The selection of filters 
available in the size required for a 96-well plate is limited in both quantity and spectral 
selectivity. Fortunately, we managed to find a 5 x 7 inch green filter (Edmund Optics 
cat. no. NT46-624, 470 - 550 nm FWHM) having a transmittance which aligned with the 
absorbance spectrum of eosin Y and eosin-(KLAKLAK)2 (Figure 2-2). Although the 
green filter does show additional transmittance at longer wavelengths, this region is not  
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Figure 2-1: Light irradiation setup designed for excitation of photosensitizers in a 
high throughput 96-well plate format. (At left) An air hose was used for direct cooling 
of the lamp to prevent overheating, and water lines to and from a flowing water filter 
(steel box directly below lamp). (At right) Sample irradiation in a 96-well plate with lid, 
color filter, and diffusing glass, always performed with the room darkened.  
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Figure 2-2: Absorbance and transmittance spectra of reagents and filter used for 
photosensitizing assays. (a) Normalized absorbance spectra for eosin Y, 5(6)-carboxy-
eosin Y, and eosin-(KLAKLAK)2. (~5 µM for each sample) (b) Overlay of eosin Y and 
eosin-(KLAKLAK)2 absorbance (left axis) with the green filter transmittance (right 
axis). 
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absorbed by eosin Y (Figure 2-2), nor did light alone without reagents have any 
significant effects in any experiment performed. It is interesting to note that the addition 
of a carboxylic acid to eosin Y results in a small shift in the maximum from 517 to 520 
nm. However, the conjugation of 5(6)-carboxy-eosin Y to the N-terminus of 
(KLAKLAK)2 results in a larger shift from 520 to 526 nm, indicating a more significant 
alteration of absorbance properties after conjugation to the peptide. The spectral output 
of the lamp through the water filter, or in addition to green or red filters is shown in 
Figure 2-3. The red filter (Edmund Optics cat. no. NT46-622, cut-on 625 nm) was 
applied for the PS chlorin e6 (Ce6), used for an experiment discussed later in section 3. 
The spectral analyzer in our possession could only measure from 500-800 nm, so it was 
not possible to quantify how much infrared light was absorbed by the water filter. 
However, sample temperature remained relatively constant over the 30 min irradiation, 
rising only ~4-5 degrees Celsius, with a range of ~25-29 degrees Celsius over the 
duration of the experiment. In comparison, the lamp itself after the experiment is very 
hot and cannot be touched without being burned, indicating that the sample is protected 
from the large majority of heat produced by the lamp.  
 
2.2.2 Eosin-(KLAKLAK)2 kills Gram-negative and Gram-positive bacteria upon 
light irradiation 
The photodynamic activity of eosin-(KLAKLAK)2 was tested against A. 
baumannii, P. aeruginosa, and E. coli (Gram negative)  as well as S. aureus, and S. 
epidermidis (Gram positive). Eosin Y was used as an unconjugated control. The  
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Figure 2-3: Spectra of quartz-halogen lamp in the presence and absence of light 
filters used for different PS. Spectra represent light after passage through the water 
filter and diffusing glass, shown with and without green and red filters in place.  
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bactericidal activity of the tested compounds was determined both in the dark and after 
irradiation at 525 nm for 30 min (525 nm corresponds to the excitation maximum of 
eosin Y). As shown in Figure 2-4, eosin Y alone or (KLAKLAK)2 alone had no 
significant effects on cell viability at 10 M in the absence or presence of light. 
Similarly, eosin-(KLAKLAK)2 had little activity toward S. aureus or E. coli in the dark 
below 10 M. However, the antimicrobial activity of eosin-(KLAKLAK)2 towards both 
strains was greatly enhanced with irradiation at 525nm, as the peptide killed 99.9 to 
99.999% of bacteria at 1 M. As expected for a light-induced process, the extent of 
photoinactivation was dependent on the irradiation time and increasing light exposure 
increased killing (Figure 2-4d). Similar results were obtained with A. baumannii, P. 
aeruginosa, and S. epidermidis (Figure 2-5). Dark toxicity of Eosin-(KLAKLAK)2 
against the Gram negative strains E. coli and Ps. aeruginosa occurred at 10 µM or less 
(Figures 2-1b and 2-2a). Even greater dark toxicity was observed towards the Gram 
negative A. baumannii, with 99% killing at 1 µM, a greater extent of killing than 
observed from (KLAKLAK)2 alone for this strain (Figure 2-2b).  
 
2.2.3 Eosin-(KLAKLAK)2 associates with bacteria to a greater extent than eosin 
Y 
In order to investigate a potential cause for the difference in activity between 
eosin Y and eosin-(KLAKLAK)2, the association of these two compounds with bacteria 
was characterized. Eosin-(KLAKLAK)2 and eosin Y were incubated with 10
8 
CFU/mL 
of E. coli or S. aureus under conditions identical to those used for photoinactivation  
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Figure 2-4: Eosin-(KLAKLAK)2 kills bacteria upon light irradiation while eosin Y 
does not. (a) Survival fraction of S. aureus (10
8
 CFU/mL) after exposure to eosin-
(KLAKLAK)2 in the dark or irradiated with visible light for 30 min. (b) Identical 
experiment performed with E. coli (10
8
 CFU/mL). (c) Effects of (KLAKLAK)2 (10 μM) 
or eosin Y (10 μM) on the survival of S. aureus or E. coli after 30 min incubation in the 
absence or presence of light. (d) Photoinactivation of E. coli (10
8
 CFU/mL) by eosin-
(KLAKLAK)2 (1 μM) as a function of irradiation time and fluence. 
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Figure 2-5: Eosin (KLAKLAK)2 kills a broad spectrum of bacteria. Survival fraction 
of Ps. aeruginosa (a), A. baumannii (b), and S. epidermidis (c) (10
8
 CFU/mL for each) 
after exposure to eosin-(KLAKLAK)2 in the dark or irradiated with visible light for 30 
min. 
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assays. The mixtures were centrifuged to separate the molecules present in solution 
(soluble fraction) to those bound to bacteria (pellet fraction). The amount of eosin- 
(KLAKLAK)2 or eosin Y associated with bacteria was then determined by measuring 
the fluorescence present in the pellet fraction. The concentrations tested were in the 
range of 0.1 to 1 M for eosin-(KLAKLAK)2 and 0.1 to 10 M for eosin Y. These 
conditions correspond to peptide to bacteria ratios at which no killing is detected in the 
dark. The signal detected is therefore proportional to the binding of eosin-(KLAKLAK)2 
or eosin Y to live bacteria as opposed to the binding of these compounds to dead cells. 
As shown in Figure 2-6, eosin-(KLAKLAK)2 associates with E. coli or S. aureus to a 
greater extent than eosin Y. For instance, eosin-(KLAKLAK)2 partitions equally 
between soluble and bacteria-bound fractions at 1 M while eosin Y is mostly present in 
solution at this concentration (Figure 2-6a). These data therefore suggest that 
(KLAKLAK)2 enhances the binding of eosin Y to bacteria. Moreover, the amount of 
eosin-(KLAKLAK)2 bound to E. coli at 1 M is equivalent to that obtained for eosin Y 
at 10 M (Figure 2-6b). It is interesting to note that, at these respective concentrations, 
eosin-(KLAKLAK)2 photo-inactivates 99.9% of bacteria while eosin Y has no photo-
induced activity (see Figure 2-4). These results therefore suggest that (KLAKLAK)2 
enhances the photodynamic activity of the photosensitizer. 
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Figure 2-6: Eosin-(KLAKLAK)2 has a higher propensity to bind to bacteria than 
eosin Y. (a) Partitioning of eosin Y and eosin-(KLAKLAK)2 between soluble (S) and 
bacteria-bound (pellet, P) fractions. Bacteria (10
8
 CFU/mL) were incubated with 1 μM 
of eosin Y or eosin-(KLAKLAK)2. The samples were centrifuged to separate the S and P 
fractions and placed in a multi-well plate. The fluorescence of each fraction was imaged 
on a fluorescence scanner. The fluorescence image obtained is represented as an inverted 
monochrome (dark contrast = bright fluorescence). (b) Fluorescence intensity associated 
with bacteria (pellet fraction) as a function of eosin-(KLAKLAK)2 or eosin Y 
concentration. E. coli (■ eosin-(KLAKLAK)2, □ eosin Y) and S. aureus (▲ eosin-
(KLAKLAK)2, Δ eosin Y) were used at 10
8
 CFU/mL and the fluorescence intensities 
reported are those obtained when the samples are kept in the dark (no bacterial killing is 
obtained under these conditions). The percentage of killing achieved when the same 
samples are exposed to light for 30 min are highlighted with arrows (these numbers 
correspond to the results obtained in Figure 1-1). Numbers depicted at 1 µM indicate 
difference in fluorescence from eosin Y, relative to E. coli and S. aureus. 
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2.2.4 Eosin-(KLAKLAK)2 photoinactivates bacteria without causing significant 
photohemolysis 
 
In order to test the specificity of the compounds between bacterial and 
mammalian cells, the photo-hemolytic activities of eosin-(KLAKLAK)2 and eosin Y 
were assessed. For these assays, RBC suspensions containing 2.5 million cells per 
milliliter were used (this corresponds to a 2000-fold dilution of the concentration of lipid 
to eosin- (KLAKLAK)2 ratios similar to that expected in the bacterial inactivation assays 
(see discussion for details). The photosensitizers Chlorin e6 (Ce6) and methylene Blue 
(MB) were also used for comparison. Ce6 (Φ∆ ~0.65)
7
 photolyses RBCs readily and this 
compound was therefore was used as a positive control.
74
 MB (Φ∆ ~0.52) 
7
 on the other 
hand, is not significantly photohemolytic and it has been successfully used for blood 
decontamination.
25
 MB was therefore used to assess the stringency of our 
photohemolysis assay. Ce6 showed approximately 70% and 100% photohemolysis at 1 
µM and 10 µM, respectively, while photohemolysis by MB was 20% and 45% at these 
concentrations. Eosin-(KLAKLAK)2 showed less photohemolysis than MB, with less 
than 10% photohemolysis at 1 µM or lower, and 40% at 10 µM (Figure 2-7b). Eosin-
(KLAKLAK)2 also showed the lowest hemolysis in the dark with only 5% hemolysis at 
10 µM. Interestingly, eosin Y gave similar results to eosin-(KLAKLAK)2. These data 
therefore suggest that conjugation of (KLAKLAK)2 to eosin Y does not significantly 
increase the photolytic activity of the photosensitizer towards erythrocytes. 
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Figure 2-7: Eosin-(KLAKLAK)2 shows a better response to the presence of bacteria 
in photohemolysis assays than the most promising PS for blood decontamination, 
methylene blue. (a) Hemolytic activities of eosin-(KLAKLAK)2 and eosin Y in the dark 
or after 30 min irradiation with light. Suspensions of RBCs (0.05% by volume) were 
prepared with or without E. coli (10
8
 CFU/mL) present. (b) Comparison of eosin-
(KLAKLAK)2 hemolytic activity to chlorin e6 (Ce6) and methylene blue (MB). 
Experiments were performed in the same way as in (a). 
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In order to address the issue of specificity more directly, a suspension of E. coli 
(10
8
 CFU/mL) was added to the RBCs before mixing with PS or peptide conjugate for 
light irradiation. The photo-hemolytic activity and bacterial photoinactivation were 
measured after irradiation. As shown in Figure 2-7, the photo-hemolytic activity of 
eosin-(KLAKLAK)2 was reduced in the presence of E.coli. For instance, the 
photohemolysis obtained at 10 M eosin-(KLAKLAK)2 was reduced from 
approximately 40% to 10% in the presence of bacteria. On the other hand, more 
than99% bacterial photoinactivation was achieved. These results therefore suggest that  
eosin-(KLAKLAK)2 destroys bacteria preferentially over red blood cells. In order to 
confirm that the reduction in photohemolysis observed was not a general phenomenon 
simply caused by the addition of E. coli, Ce6 was here again included as a control. It has 
been shown that E. coli does not take up Ce6 at the concentrations used in our assays.
12
 
We therefore expected that presence of E. coli should not affect the photo-hemolytic 
activity of Ce6. Indeed, no significant change in the photohemolysis activity of Ce6 was 
observed in the presence of E. coli (Figure 2-7b). 
In order to test whether the reduced hemolysis by eosin-(KLAKLAK)2 in the 
presence of E. coli and S. aureus is caused by the association of the peptide with the 
bacteria, samples of eosin-(KLAKLAK)2 and cells were examined by microscopy before 
and after irradiation (Figures 2-8 and 2-9). The fluorescent photosensitizer rose bengal 
(RB) was also observed with cells in order to compare eosin-(KLAKLAK)2 with a 
lipophilic PS known to be non-specific in its binding.
75
 As shown in Figure 2-8a, the 
fluorescence signal of eosin-(KLAKLAK)2 is associated with bacteria (also visible in  
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Figure 2-8: Eosin-(KLAKLAK)2 binds more to E. coli than RBCs. Bright-field and 
fluorescence imaging of RBCs (0.05% by volume) mixed with E. coli (10
8
 CFU/mL) 
and (a) eosin-(KLAKLAK)2 (1 μM) or (b) Rose Bengal (1 μM). Images were acquired 
after 30 min incubation in the absence or presence of light. SYTOX Blue was added to 
the samples afterward to detect dead bacteria. Intact RBCs in the bright field images 
have a dark contrast while lysed ghosts are transparent and only visible as rings. Scale 
bar is 10 μm. 
  
30 
 
 
Figure 2-9: Eosin-(KLAKLAK)2 binds more to S. aureus than RBCs. Bright field 
and fluorescence imaging of RBCs (0.05% by volume) mixed with S. aureus (10
8
 
CFU/mL) and (a) eosin-(KLAKLAK)2 (1 μM) and (b) Rose Bengal (1 μM). Images 
were acquired after 30 min incubation in the absence or presence of light. SYTOX® 
Blue was added to the samples afterwards to detect dead bacteria. Intact RBCs in the 
bright field images have a dark contrast while lysed ghosts are transparent and only 
visible as rings. Scale bar is 10 μm. 
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bright field image) while RBCs present in the sample are not stained by eosin-
(KLAKLAK)2. In comparison, RB stains the plasma membrane of RBCs. This therefore 
indicates that eosin-(KLAKLAK)2 binds to bacteria to a much greater extent than to 
RBCs. In addition, most of the RBCs present after irradiation have a dark contrast 
consistent with these cells being intact and only a few lysed ghosts can be observed 
(ghosts are transparent but their plasma membrane remains visible). These results 
therefore confirm that the extent of photohemolysis of RBC in the presence of E. coli is 
limited. Moreover, bacteria were stained by SYTOX® Blue after irradiation but not 
before. SYTOX® Blue is a nuclear stain that does not penetrate live cells but that can 
stain cells with a compromised membrane. These data therefore indicate the bacteria 
present were photo-inactivated. A colony-forming assay after serial dilutions of the 
sample confirmed that more than 99% of the bacteria were killed. Overall, these data 
suggest that, while eosin-(KLAKLAK)2 is capable of lysing the membrane of RBCs at 
certain peptide to cell ratios, the photolytic activity of this compound is more 
pronounced toward bacteria. In particular, this appears to be consistent with a 
preferential association of the peptide with bacterial cells over erythrocytes. 
 
2.2.5 Eosin-(KLAKLAK)2 is less phototoxic towards mammalian cells than 
bacteria 
The phototoxicity of eosin-(KLAKLAK)2 was tested with HaCaT (human 
keratinocytes), COS-7 (monkey fibroblasts) and COLO 316 (human ovarian carcinoma). 
Cells were incubated with eosin Y, (KLAKLAK)2, and eosin-(KLAKLAK)2 and  
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Figure 2-10: Eosin-(KLAKLAK)2 is not phototoxic toward COLO 316, HaCaT, or 
COS-7 cell lines at concentrations required to kill bacteria. (a) Fluorescence 
microscopy imaging (20×) of HaCaT cells incubated with eosin-(KLAKLAK)2 (1 or 10 
μM) for 30 min with light exposure. Cells were coincubated with Hoescht (pseudo 
colored purple here) and SYTOX Green dyes immediately following (30 min) or 18 h 
after illumination. Percent survival of cells was determined by counting the cells with 
compromised plasma membranes (stained by SYTOX Green) compared to the total (all 
cells are stained by Hoescht). Scale bar is 100 μm. (b) Survival of COLO 316, HaCaT, 
and COS-7 cells with eosin-(KLAKLAK)2 (10 μM) in the dark (c) Survival of COLO 
316, HaCaT, and COS-7 cells exposed to eosin-(KLAKLAK)2 (1, 5, and 10 μM) for 30 
min with light irradiation. Cell viability was assessed 30 min and 18 h after exposure. 
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irradiated under the same conditions used for bacterial photoinactivation. The viability 
of cells was assessed before and after irradiation using SYTOX® Green exclusion assays 
(Figure 2-10a), where the cell-impermeable SYTOX
®
 Green only fluoresces after 
binding to DNA in cells whose membranes have been compromised, indicating cell 
death. In the dark the compounds showed no toxicity towards the cells in the range of 
concentration tested (1 to 10 M) (Figure 2-10b). In the light some toxicity was 
observed only at higher concentrations (5 or 10 µM) for COS-7 and HaCaT, while 
COLO 316 showed no toxicity even at 10µM eosin-(KLAKLAK)2 (Figure 2-10c). 
The propensity of eosin-(KLAKLAK)2 to be internalized by mammalians cells was 
evaluated by fluorescence microscopy (Figure 2-11a). The peptide TAT labeled with 
eosin- Y (eosin-TAT) was used as a positive control. TAT is an arginine-rich peptide 
known to be endocytosed efficiently by mammalian cells.
69
 After incubation with cells 
for 30 min, eosin-TAT distributed in a punctate manner inside cells, indicative of the 
accumulation of the compound inside endocytic organelles (Figure 2-11a). In contrast, a 
fluorescence signal at least 10-fold less than this intensity was detected for eosin-
(KLAKLAK)2 under identical conditions (Figure 2-11b). Together, these data suggest 
that eosin-(KLAKLAK)2 associates minimally with mammalian cells and that the 
photodynamic activity of eosin-(KLAKLAK)2 toward mammalian cells is significantly 
less than that obtained with bacteria. 
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Figure 2-11: Eosin-(KLAKLAK)2 is taken up by cells significantly less than eosin-
TAT. (a) Bright-field and fluorescence microscopy imaging of COLO 316 cells (100×) 
incubated with eosin-(KLAKLAK)2 (1 μM) or eosin-TAT (1 μM) for 30 min. Scale bar 
is 10 μm. (b) Total fluorescence intensity of cells incubated with eosin-(KLAKLAK)2 or 
eosin-TAT (1 μM) for 30 min (two-tailed t test, * = p < 0.05, ** = p < 0.01). 
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2.3 Discussion 
Bacterial photoinactivation assays show that a moderate dose of light can reduce 
the lethal concentration of eosin-(KLAKLAK)2 towards bacteria by more than 10 fold. 
The peptide (KLAKLAK)2 greatly enhances the photodynamic activity of eosin Y as this 
PS is not very phototoxic on its own. Moreover, eosin-(KLAKLAK)2 caused the 
photoinactivation of Gram-positive and Gram-negative strains to a similar extent. Our 
results therefore suggest that, unlike what has been observed for other cationic PS, the 
outer membrane of the gram-negative bacteria might not represent a significant barrier to 
the penetration of the peptide conjugate.
76-78
 This is consistent with the reported MICs of 
(KLAKLAK)2 being similar for Gram-negative and Gram-positive bacteria.
70
 The 
binding of eosin-(KLAKLAK)2 with E. coli and S. aureus was greater than that of eosin 
Y alone, indicating that the peptide promotes the association of the PS to bacteria. The 
peptide therefore appears to enable the photodynamic activity of the photosensitizer by 
acting as a targeting agent.  
Based on the models proposed in the literature for (KLAKLAK)2 and related 
antimicrobial peptides, one can envision that eosin-(KLAKLAK)2 binds to bacterial lipid 
bilayers. At the low concentration at which photoinactivation is achieved, however, the 
peptide itself is not able to cause the formation of lytic pores, as no antimicrobial activity 
is detected in the dark. Yet, binding experiments reveal that, with equal amount of eosin-
(KLAKLAK)2 and eosin Y bound to bacteria, eosin-(KLAKLAK)2 is able to photo-
inactivate bacteria but eosin Y cannot. A possible explanation for this effect might be 
that (KLAKLAK)2 contributes to destabilizing the bacterial membrane. (KLAKLAK)2 
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could for example, promote lysis or enhance the damaging effect of ROS generated by 
the photosensitizer. We envisioned for instance, that the A-AMP-disrupted bacterial 
membrane might become more susceptible to the ROS produced by the PS agent, while 
ROS-induced membrane damage might also facilitate membrane disruption by the A-
AMP. Another possible explanation involves the idea that (KLAKLAK)2 might position 
eosin Y in a cellular location that eosin Y alone is not otherwise able to access and that 
the generation of ROS at this particular location kills cells more effectively. Further 
studies are required to validate these models and elucidating which of these principles 
can be exploited should be useful for the design of optimized PDT agents.  
An important aspect of antimicrobial PDT is the specificity of the PS toward 
bacterial cells. Ideally, the photodynamic drug should kill bacteria without damaging 
host tissues. In order to compare the photodynamic activity of eosin-(KLAKLAK)2 
towards bacteria to that obtained with RBCs, photohemolysis assays were performed 
with human erythrocytes. Under the assumption that a lipid bilayer is a primary target of 
the photodynamic activity of eosin-(KLAKLAK)2, conditions were chosen to obtain 
peptide to lipid ratios similar between bacterial photoinactivation and photohemolysis 
assays. RBCs were, for instance, diluted 2,000-fold in comparison to human blood. One 
can therefore expect that hemolysis would be more pronounced at the low RBC 
concentration used than at the high concentration of human blood and that the assays 
used are relatively stringent. Approximately 10% hemolysis was obtained at 1 M eosin-
(KLAKLAK)2, the concentration required to achieve approximately 99.99% inactivation 
of E. coli or S. aureus. Due to the stringent conditions of the hemolysis assays, this low 
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level of hemolysis accompanied by significant bacterial inactivation therefore suggests 
that bacterial photoinactivation can be achieved under conditions where RBCs can be 
spared. Yet, a concern is raised by the observation that photohemolysis increases to 40% 
as the concentration of eosin-(KLAKLAK)2 is increased to 10 M. The concentration 
window at which bacterial killing can be achieved without adverse effects to RBCs 
might therefore be relatively narrow. Interestingly though, mixing experiments between 
bacteria and erythrocytes show that eosin-(KLAKLAK)2 associates with bacteria to a 
greater extent than red blood cells. Eosin-(KLAKLAK)2 binding to bacteria presumably 
reduces the concentration of compound present in solution or on the surface of RBCs. 
Consequently, photohemolysis with eosin-(KLAKLAK)2 at 10 µM was reduced to 10% 
when bacteria were present. More than 99% bacterial killing could be achieved under 
these conditions, further confirming that eosin-(KLAKLAK)2 can inactivate bacteria 
before significant damage is observed for a human cell.  
To further address the issue of specificity, the photodynamic activity of eosin-
(KLAKLAK)2 was tested against epithelial cells, keratinocytes and fibroblasts. As with 
RBCs, one might expect eosin-(KLAKLAK)2 to possibly interact with the plasma 
membrane of these cells. In addition, relatively large and amphiphilic molecules like 
eosin-(KLAKLAK)2 can be endocytosed by cells. As a matter of fact, lysine and 
arginine-rich peptides, previously used to improve the targeting of PS such as chlorin e6 
to bacteria, are well known to be effectively endocytosed by human cells.
79-81
 
Unfortunately, PS that accumulate in the endocytic pathway can photo-lyse endocytic 
organelles such as lysosomes and this might in turn cause cell-death.
51, 69, 82
 Consistent 
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with this idea, cells that have endocytosed PS conjugated to lysine or arginine-rich 
polymers can be killed readily upon irradiation.
51, 69, 83
 Moreover, the photolysis of 
endocytic organelles raises a concern related to the penetration of antimicrobial peptides 
inside human cells. In particular, it has been shown that antimicrobial peptides that 
escape the endocytic pathway might gain access to mitochondria, disrupt the membrane 
of these organelles, and induce apoptosis.
72
 For instance, (KLAKLAK)2 causes cellular 
apoptosis when combined with agents capable of delivering this peptide in the cytoplasm 
of human cells, although (KLAKLAK)2 is not toxic without these delivery agents.
84, 85
 
We were therefore concerned that eosin-(KLAKLAK)2 might be taken up into 
mammalian cells, lyse endocytic organelles upon irradiation, and possibly cause cell 
death. To test whether eosin-(KLAKLAK)2 would be endocytosed by cells and in order 
to assess the phototoxicity of the compound, eosin-(KLAKLAK)2 was incubated with 
different cell lines and uptake was examined by fluorescence microscopy. While 
internalization of the positive control eosin-TAT could be readily observed, eosin-
(KLAKLAK)2 was not significantly internalized by cells. Also, the viability of cells was 
not significantly affected by irradiation for 30 min with incubation at 1 M eosin-
(KLAKLAK)2 (conditions at which more than 99.9% bacterial photoinactivation is 
achieved). These results therefore suggest that bacterial cells are more susceptible to the 
photodynamic activity of eosin-(KLAKLAK)2 than mammalian cells. At higher 
concentrations (5 or 10 M), the phototoxicity towards mammalian cells was increased 
in a cell-dependent manner. In order to design optimal compounds, it will be interesting 
to determine in future studies what causes the differences observed in phototoxicity. 
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Nonetheless, these results suggest that the photoinactivation of bacteria without human 
tissue damage might be achievable. Of course, in vivo experiments will be necessary to 
validate this idea. 
Overall, our results establish that the conjugation of eosin Y to the antimicrobial 
peptide (KLAKLAK)2 increases the photodynamic activity of eosin Y towards E. coli 
and S. aureus considerably. A possible advantage of antimicrobial peptides over other 
polycationic polymers might involve a reduced propensity to be endocytosed by human 
cells and, consequently, a reduced phototoxicity towards these cells. In addition, it will 
be interesting to test whether peptides that have a higher antimicrobial activity in the 
dark would further reduce the concentration of PS-peptide conjugate required to achieve 
bacterial photoinactivation. 
 
2.4 Materials and methods 
Cell culture reagents were purchased from Invitrogen. Peptide synthesis reagents 
were from Novabiochem. The compound 5,6-carboxy-eosin was purchased from Marker 
Gene Technologies. All other reagents were from Sigma. COS-7 and COLO 316 were 
obtained from ATCC. HaCaT cells were a generous gift from Joan Massagué (Memorial 
Sloan-Keterring Cancer Center). Whole blood was purchased from Gulf Coast Regional 
Blood Center (Houston, TX). 
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2.4.1 Spectroscopy 
Absorbance and transmission measurements were recorded using a Shimadzu 
UV-1700 UV-VIS spectrophotometer in conjunction with UV Probe 2.21 software. 
Samples (150 µl) were placed in Fisherbrand
®
 utlramicro quartz cuvettes with a 1 cm 
pathlength. Blank readings were performed with solvent only, usually water except for 
Ce6, which was suspended in phosphate buffer (100 mM NaCl, 10 mM Na2HPO4, pH 
7.4) to permit solubility. Transmittance spectra of the filters were recorded by 
positioning the filters in slots directly in front of the detector. Since positioning of the 
filter required the sample compartment door to be open, both background and filter 
transmittance measurements were performed in a darkened room to reduce noise to the 
detector. 
 
2.4.2 Peptide design and synthesis 
H2N-KLAKLAKKLAKLAK-NH2 (“(KLAKLAK)2”) was synthesized by Fmoc 
solid phase peptide synthesis using rink amide MBHA resin according to previously 
reported protocols (Novabiochem). Eosin-(KLAKLAK)2 was synthesized by coupling of 
5,6-carboxy-eosin Y to the N-terminal residue of the peptide. H2N-
KLAKLAKKLAKLAK-NH2 and eosin-(KLAKLAK)2 were purified using HPLC and 
their mass was confirmed by MALDI-TOF. Because possible differences in the eosin Y 
isomers may produce different membrane affinities, the isomer of the labeled peptide 
that first eluted from HPLC was used for all experiments. H2N-KLAKLAKKLAKLAK-
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NH2 expected mass: 1522.08, observed mass: 1523.18. Eosin-(KLAKLAK)2 expected 
mass: 2198.82, observed mass: 2196.67.  
 
2.4.3 Bacterial strains 
Escherichia coli BL21 DE3 was obtained from Agilent. Pseudomonas 
aeruginosa (ATCC 27853), Staphylococcus aureus subsp. aureus (ATCC 29213), and 
Staphylococcus epidermidis (ATCC 12228) were purchased from the American Type 
Culture Collection. Multidrug-resistant Acinetobacter baumannii AYE strain (ATCC 
BAA-1710) was a gift from Dr. Ry Young at Texas A&M University Center for Phage 
Technology. E. coli and S. aureus were grown in Luria-Bertani broth (LB), Ps. 
aeruginosa and A. baumannii were grown in tryptic soy broth, and S. epidermidis in 
nutrient broth. Glycerol stocks were established for each strain and used to streak agar 
plates. Colonies from plates were used to inoculate overnight cultures which were grown 
aerobically at 37
o
C. Fresh cultures were inoculated the next day in a 1:1000 dilution of 
overnight culture and used for experiments after growth to mid log phase (O.D.600 ~0.4-
0.6). 
 
2.4.4 Bacterial photoinactivation assay 
Bacteria were grown as described above in 14 mL round-bottom Falcon
®
 culture 
tubes in their respective media, then centrifuged at 1500 g for 10 min and resuspended in 
sterile phosphate buffer (100 mM NaCl, 10 mM Na2HPO4, pH 7.4). This wash procedure 
was repeated a second time and this stock suspension was used to make suspensions at 
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the OD required for the particular strain to have approximately 10
8
 CFU/mL (colony 
forming units were determined by plating 10-fold serial dilutions of cultures on agar 
plates as described below). Peptide solutions (10X, 22 l) were prepared in wells of a 
96-well plate before addition of 200 l of bacteria in phosphate buffer (~108 CFU/mL). 
Samples were allowed to incubate for approximately 3-5 min before irradiation to allow 
for peptide binding, and micro stir bars (2x2 mm, Cowie
®
 via Fisher) were added for 
continued aeration during irradiation. The lipid to peptide (L/P) ratio under these 
conditions is 1:1 when the peptide or PS concentration is approximately 3 µM (these 
calculations assume 25 x 10
6
 lipids per bacteria). 
Irradiation was achieved using a homemade setup with a 600 W halogen lamp 
(Utilitech #0320777). The lamp was suspended by clamps and air-cooled during 
operation. A homemade water filter was placed below the lamp to filter out IR with 
continuous exchange of the water supply. A stir plate was placed underneath the water 
filter to hold the samples for illumination. Samples were placed in a 96-well plate with a 
lid. A 5x7 inch green filter (Edmund Optics cat. no. NT46-624, 470-550nm FWHM) was 
placed on top of the lid for excitation of eosin. A single pane of 1/16 inch diffusing glass 
was placed on top of the green filter to provide an even distribution of light intensity.  
Experiments detecting the 
1
O2 production from Rose Bengal via reaction with RNO 
demonstrated that this setup provides even distribution of light across all 96 wells (data 
not shown). Samples were stirred at 200 rpm and set at a distance of 20 cm from the 
light source. Exposure time was 30 min for all killing assays. 
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After samples were illuminated or kept in the dark for 30 min, 30 l of each 
sample was added to 270 l of phosphate buffer in a separate 96-well plate. Further 10-
fold serial dilutions of the samples were made in phosphate buffer to give samples 
ranging from 10
1
-10
5
 in dilution factor. From each dilution, 50 l was removed and 
spread on an agar plate, then incubated overnight at 37
o
C. Colonies were counted the 
next morning to determine the remaining CFU/mL. Plates without peptide treatment 
were included as a negative control for sample comparison to determine percent 
survival.  
 
2.4.5 Partitioning assay 
Mixtures of bacteria and peptide or PS were prepared in the same manner as the 
photoinactivation assays above (222 µl total volume). Samples were then centrifuged at 
1500 g for 10 min, and 200 µl of supernatant was transferred to a 96-well plate. Any 
remaining supernatant was removed, and the pellet was resuspended in 200 µl of 
phosphate buffer. The fluorescence intensity of the pellets was measured with a 
microplate reader (Promega® Glomax-Multi®) using the green filter set (Ex 525 / Em 
580-640 nm). Absorbance values were ≤ 0.100 at 525 nm to avoid the inner filter effect. 
To ensure that quenching was not occurring, two-fold serial dilutions of samples were 
performed. A linear decrease in fluorescence was observed, indicating that no quenching 
occurred in the resuspended pellet. Experiments were performed in triplicate. 
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2.4.6 Photohemolysis assay 
A concentration of 0.05 % by volume of RBCs was used for hemolysis 
experiments. This RBC concentration gives a similar L/P ratio to that used in 
photoinactivation assays, where the L/P ratio is 1:1 when the peptide or PS concentration 
is approximately 3 µM (assuming ~ 5 x 10
8
 lipids per RBC). RBCs (200 µl) were placed 
in a well of a 96-well plate, and 22 µl of 10 X peptide-conjugate or PS was added and 
mixed. RBCs were incubated for 5 minutes before illuminating (or keeping in darkness) 
for 30 min using the halogen lamp setup described above. The extent of hemolysis was 
determined by centrifuging samples at 1500 g for 10 min, then reading the absorbance of 
hemoglobin in the supernatant at 450 nm. Untreated RBCs were included as a negative 
control for both dark and illuminated samples. RBCs treated with 0.1% Triton X-100 
were used as a positive control for 100% lysis. The data represent experiments in 
triplicate with their respective standard deviations. 
Mixed RBC and bacteria samples were prepared similarly, with 200 µl of 
bacteria (10
8
 CFU/mL) in PBS placed in a well of a 96-well plate, then 11 µl of 20 X 
RBCs added and mixed together. Peptide-conjugate or PS (11 µl of 20 X stock solution) 
was added only after the RBCs and bacteria were mixed to ensure equal opportunity for 
binding of the peptide to either the RBCs or bacteria. Illumination by halogen lamp and 
measurement of hemolysis was carried out in the same manner. In order to determine the 
amount of bacteria killed after illumination, parallel samples were included to determine 
the CFU/mL remaining by performing serial dilutions on agar plates, as described for 
bacteria killing assays. Experiments were performed in triplicate. 
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For imaging of RBCs or mixed RBC and bacteria samples, a 384-well plate with 
a glass bottom was used to enable use of the 100X oil-immersion objective. Samples 
were prepared in the same manner as above, but scaled down from 220 µl to 55 µl total 
volume because of the well size. Cells were imaged before and after illumination for 30 
min under the halogen lamp to observe binding and/or killing. SYTOX® Blue was 
incubated for 15 min at room temperature before imaging as an indicator of bacterial cell 
death. Intact erythrocytes have a dark contrast in the bright field image while lysed 
ghosts do not.
69
  
 
2.4.7 Microscopy 
Imaging was performed on an inverted epifluorescence microscope (Model IX81, 
Olympus, Center Valley, PA). The microscope is equipped with a heating stage 
maintained at 37°C. Images were captured with a Rolera-MGI Plus back-illuminated 
EMCCD camera (Qimaging, Surrey, BC, Canada). Imaging was performed using bright 
field imaging and the following fluorescence filter sets: DAPI (Ex = 360 ± 20 nm / Em = 
460 ± 30 nm), FITC (Ex = 488 ± 10 nm / Em = 520 ± 20 nm), and RFP (Ex = 560 ± 20 
nm / Em = 630 ± 35 nm). Fluorescence excitation was achieved with a 100 W mercury 
lamp (Leeds Precision Instruments # L202 Osram) and with neutral density filters (ND 
1, 2, 3 and 4 on the instrument, corresponding to 100, 25, 12.5 and 5% transmittance).  
Images were captured with SlideBook 4.2 software (Olympus, Center Valley, PA).  
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2.4.8 Cell-based assays 
Mammalian cells were cultured in Dulbecco’s Minimum Essential Media 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and maintained at 37C in a 
humidified environment with 5% CO2. For viability experiments cells were plated in 
sterile 96-well plate so that the cells were approximately 80% confluent after 24 or 48 h. 
Cells were washed twice with PBS and once with Leibovitz’s L-15 medium, before 
addition of the desired concentration of eosin-(KLAKLAK)2 in L-15. The cells were 
then kept in the dark or illuminated for 30 min in the same manner as the bacterial 
inactivation experiments. Afterwards, the cells were washed out with PBS twice and 
once with L-15 before incubation with SYTOX Green and Hoechst in L-15 media 
according to the manufacturer’s instructions. SYTOX Green is cell-impermeable and 
only stains cells with a compromised plasma membrane while Hoechst stains all cells. 
Cells were imaged with a 20X objective using bright field and fluorescence in DAPI and 
FITC channels. Ten to twenty images were acquired in the green and blue channels for 
each experiment. The total number of cells in a given image was determined from the 
blue channel image (Hoechst) by counting the number of blue nuclei present. The 
number of dead cells was determined by identifying cells containing a green fluorescent 
nucleus stained by SYTOX green. Cell viability was determined by establishing a ratio 
of dead cells/total number of cells for each sample (at least 1000 cells were counted in 
each experiment and each experiment was repeated 3 times). 
For comparison of cellular uptake between eosin-TAT and eosin-(KLAKLAK)2, 
cells were plated in 8-well glass bottom dishes (Lab-Tek) 24 or 48 h prior to 
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experiments. Cells were washed twice with PBS and once with L-15, then incubated 
with 1 µM eosin-TAT or eosin-(KLAKLAK)2 in L-15 for 30 min. After incubation cells 
were washed twice with PBS and once with L-15. Fluorescence (IRFP channel) and 
bright field images were captured at 100X. For comparison of uptake, the fluorescence 
intensity per cell was determined with the Slidebook software by measuring the total 
fluorescence intensity present in each cell. This was performed by first creating outlines 
for each cell, which were converted to masks of the whole cell with the software.  
Background removal was performed by subtracting the highest background value from 
the IRFP channel, then using the software to calculate the sum intensity of the endocytic 
organelles that remained visible within the masks and above the background. The 
intensities of all endocytic organelles were then added to obtain the total fluorescence 
intensity per cell. Approximately 50 representative cells were imaged for each condition. 
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3. MECHANISTIC INSIGHTS INTO EOSIN-(KLAKLAK)2 ACTIVITY 
 
3.1 Introduction 
In this section I describe the use of a novel application of TEM methods to 
visualize eosin-(KLAKLAK)2 in E. coli and S. aureus samples. We take advantage of 
the PS for photo-oxidation of 3,3-diaminobenzidine (DAB) to produce an osmiophilic 
polymer at the location of the PS-AMP conjugate. Secondly, the location of the PS-AMP 
is further confirmed by scanning transmission electron microscopy with electron 
dispersal X-ray spectroscopy (STEM-EDS) to locate bromine atoms that are present only 
in the eosin moiety. To our knowledge this is the first application of these methods to 
peptides, specifically an AMP in this case. This work demonstrates the usefulness of 
these methods for direct visualization of peptides in biological samples for TEM without 
the requirement of immunogold labeling. After TEM results demonstrated, perhaps not 
surprisingly, that the bacterial membrane was the primary location for eosin-
(KLAKLAK)2 binding in the dark, we turned to lipid membrane models to study the 
activity of the PS-AMP conjugate, and the respective roles of the PS and AMP.  
 
3.2 Results 
3.2.1 Eosin-(KLAKLAK)2 localizes to the outer surface of E. coli and S. aureus in 
the dark, and subsequent light excitation causes membrane disruption 
To investigate the mechanism of eosin-(KLAKLAK)2 activity, we first sought to 
determine likely molecular targets. Since AMPs have been shown to localize to both the 
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cell exterior and interior in different cases, we probed the location of eosin-
(KLAKLAK)2 during PDI experiments by TEM. To do this, we took advantage of eosin 
as part of the conjugate to visualize samples using a DAB photooxidation method. 
Suitable PS have been used to label antibodies and proteins to oxidize 3,3-
diaminobenzidine (DAB) for the formation of an osmiophilic DAB polymer at the site of 
PS activity. The enrichment of osmium staining at the site of the polymer provides a 
heightened contrast by electron microscopy.
17,9
  
Figure 3-1a depicts the DAB polymerization caused by singlet oxygen or 
superoxide production from the triplet state of eosin Y.
86
  To perform this reaction we 
followed the sequence shown in Figure 1b. The first illumination step in this process was 
carried out for only 0, 2, or 5 min to limit the damage caused by eosin-(KLAKLAK)2. 
This allowed us to examine the early stages of localization and activity. Fixation of the 
peptide with cells did not prevent eosin-(KLAKLAK)2 from polymerizing DAB during 
the second illumination step (evidenced by enhanced osmium staining in Figure 3-1b). 
Neither did the second illumination step appear to damage cells, since samples with 
eosin-(KLAKLAK)2 that were not irradiated before the fixation showed little structural 
difference compared to untreated cells by EM (Figure 3-2a). This implies that this 
method is suitable for observing the location of the eosin-(KLAKLAK)2 conjugate 
before and after the PDI process. Before light irradiation, the peptide is clearly localized 
to the exterior of the cell surface of E. coli and S. aureus (Figure 3-2a, second column). 
However, light irradiation of eosin-(KLAKLAK)2 in solution with each strain, results in 
membrane damage and lysis of the cell wall in many cases. The 2 and 5 min irradiation 
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Figure 3-1: Experimental design of DAB photo-oxidation and visualization by 
TEM. (a) Light excitation of eosin-(KLAKLAK)2 results in production of singlet 
oxygen and superoxide, which can polymerize DAB to provide an enhanced staining of 
osmium at the location of eosin-(KLAKLAK)2. (b) Light irradiation has two purposes in 
this experiment, 1) to excite eosin-(KLAKLAK)2 for photodynamic activity, then 
following fixation of samples, 2) to polymerize DAB at the location of the PS-AMP 
conjugate. 
 
 
 
 
  
51 
 
 
 
 
Figure 3-2: Localization of eosin-(KLAKLAK)2 in E. coli and S. aureus samples 
determined by DAB photooxidation. Untreated samples are shown in the left column. 
Eosin-(KLAKLAK)2 was incubated with cells, then irradiated for 0, 2, or 5 min before 
fixation with acrolein to anchor eosin-(KLAKLAK)2 in place. Cells were then washed 
and a second illumination was performed in the presence of DAB (1 mg/ml), producing 
an osmiophilic polymer for enhanced contrast by TEM at the site of eosin-
(KLAKLAK)2. Scale bars are 0.2 µm in all images. 
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times represent approximately 50% and 90% cell death as shown in the previous 
section.
10
 The membrane deformation and lysis seen here correlates with the cell death 
in section 2 and indicates a likely mechanism for cell death caused by eosin-
(KLAKLAK)2.  
In order to validate that the enhanced osmium staining at the cell surface of 
bacteria was in fact the result of the presence and activity of eosin-(KLAKLAK)2, 
STEM-EDS was used to positively identify the location of the conjugate. Scanning TEM 
(STEM) with energy dispersive X-ray spectroscopy (EDS) can be used for elemental 
analysis of biological samples to study the distribution of different atoms. Eosin Y 
contains four bromine atoms per molecule, making bromine a unique marker for the 
location of eosin-(KLAKLAK)2. Furthermore, since the presence of bromine is rare 
among bacterial species, generally limited to specialized marine bacteria,
87
 there is no 
background signal to specifically interfere with detection by STEM-EDS in E. coli or S. 
aureus, and would not be expected for most other species. In Figure 3-3a an image of a 
S. aureus cell treated with eosin-(KLAKLAK)2 is shown, with a line and square 
depicting the paths of a line and area scan, respectively, for STEM-EDS analysis (Figure 
3-3b,c). The intensity of bromine content is depicted along the path of the line scan in 
the plot to the right. The bromine intensity is greatest at the cell membrane and at the 
location of what appears to be adjacent membrane debris in the media. These results 
support the distribution made apparent by DAB polymerization and also demonstrate the 
capability of STEM-EDS to identify unique atoms on a small peptide in the context of a 
biological sample. Together, the DAB and STEM-EDS images suggest that eosin- 
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Figure 3-3: Bromine atoms in eosin-(KLAKLAK)2 serve as a marker of the peptide 
for detection by STEM-EDS in bacteria samples. (a) STEM backscatter image of S. 
aureus treated with eosin-(KLAKLAK)2 and light for 2 min. (b) EDS element profiles of 
the line scan depicted in (a) from left to right, showing the coincident intensities of Os, 
Br, and P elements at the cell wall and in extracellular material, possibly removed from 
the cell during irradiation with eosin-(KLAKLAK)2. (c) Elemental analysis by EDS for 
the square area indicated in (a), showing the distinct presence of Br from eosin-
(KLAKLAK)2 among the many other elements expected for a biological sample. 
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(KLAKLAK)2 localizes to the cell membrane in the dark, and upon light irradiation, 
causes membrane deformation and without light, and eosin Y alone is not toxic to cells 
in the light.
10
 
 
3.2.2 Conjugation of eosin Y to (KLAKLAK)2 alters the production of ROS 
We previously demonstrated that eosin Y alone showed no toxicity towards E. 
coli and S. aureus under conditions where an equivalent amount of bound eosin-
(KLAKLAK)2 caused extensive killing. To examine why this difference in toxicity 
exists, we tested the hypothesis that the production of ROS might be altered after 
conjugation of eosin Y to (KLAKLAK)2, which has been previously observed after 
conjugation of another PS to polyethyleneimine.
37
 Eosin Y is reported to produce both 
1
O2 and O2
● -
,
86
 which have each been shown to participate in PDI of bacteria and other 
microbes.
88
 To compare the production of 
1
O2 for eosin Y and eosin-(KLAKLAK)2, we 
used the RNO assay, which reports on the oxidation of RNO in the presence of 
imidazole as a result of 
1
O2 production.
89,90
 Comparison of O2
•-
 was achieved using the 
NBT assay, which detects the reduction of NBT to a formazan in the presence of 
NADH.
91,37
 These assays are suitable to use during the production of both 
1
O2 and O2
● -
 
since the RNO reaction occurs by an oxidation mechanism, while the NBT detects a 
reduction, so there is not a mixed detection in either case. 
Figure 3-4a shows that there is a decrease in the production of singlet oxygen 
from eosin-(KLAKLAK)2 relative to eosin Y alone. The effect of the 
1
O2 quencher NaN3 
is shown in the extension of the Figure 3-4a, and significantly reduces the bleaching of 
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RNO. Surprisingly, the NBT assay in Figure 3-4b shows a dramatic increase in the 
production of superoxide for eosin-(KLAKLAK)2 compared to eosin Y. The observed 
decrease in 
1
O2 and accompanying increase in O2
•-
 after conjugation to (KLAKLAK)2 
demonstrate altered triplet state reaction properties for eosin Y after conjugation. These 
changes are consistent with that observed for the PS Ce6 after conjugation to PEI,
92
 
although it is unclear whether this response to conjugation is a general characteristic for 
PS, or whether the particular response is dependent on the PS and/or peptide used. These 
results suggest a possible mechanism for the enhanced PDI activity of eosin-
(KLAKLAK)2 compared to eosin Y when equal amounts of either molecule are present 
at the membrane.  
 
3.2.3 Role of ROS in PDI of E. coli and S. aureus 
In order to study the role of 
1
O2 and O2
●-
 in the killing of bacteria by eosin-
(KLAKLAK)2, we examined the effect of quenchers upon the survival of the Gram 
negative E. coli and Gram positive S. aureus in the presence of light (Figure 3-5). The 
relative survival fraction of cultures is shown in the presence and absence of eosin-
(KLAKLAK)2 to distinguish any toxicity by the quencher alone from the activity of 
eosin-(KLAKLAK)2. Since the generation of both 
1
O2 and O2
●-
 by PS is oxygen-
dependent, we first examined the role of oxygen by displacing oxygen as well as we 
could with a N2 environment. A completely protective effect was likely not possible 
since sample handling required a limited exposure to air, allowing re-entry for some 
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Figure 3-4: Conjugation of eosin Y to (KLAKLAK)2 alters 
1
O2 and O2
•-
 production. 
Relative production of 
1
O2 from eosin Y and eosin-(KLAKLAK)2 detected by oxidation 
of RNO in the presence of imidazole. Addition of NaN3, a quencher of 
1
O2, results in a 
large reduction of the response (a). Relative production of O2
•-
 from eosin Y and eosin-
(KLAKLAK)2 detected by reduction of NBT to blue formazan in the presence of 
NADH, and specific quenching of O2
•-
 by Tiron (b). 
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Figure 3-5: The role of different ROS in eosin-(KLAKLAK)2 (”PS-AMP”)-
mediated killing of S. aureus and E. coli. Samples (10
8
 CFU/ml) of S. aureus (a) and 
E. coli (b) were irradiated with light for 30 min. Serial dilutions were made for colony 
counting and the survival fraction determined by comparison with non-irradiated 
controls. Samples without the PS-AMP are included to indicate the toxicity of the 
quenchers alone.  
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level of oxygen into the sample before irradiation. Nonetheless, our N2 environment 
resulted in a ~2-log protection of both strains, demonstrating a clear role for O2 in the 
PDI activity of eosin-(KLAKLAK)2. 
In Figure 3-5, the soluble 
1
O2 quencher imidazole (50 mM) showed no protective 
effect for S. aureus, although, E. coli obtained considerable protection from the same 
quencher. Imidazole actually enhanced the PDI against S. aureus, which is likely the 
quencher preventing some degree of PS self-bleaching that normally occurs, thus 
enhancing the life of the PS and its effects. In contrast, the membrane soluble 
1
O2 
quencher, crocetin (50 µM), was able to protect both strains. For S. aureus, this suggests 
that singlet oxygen is produced mostly within the membrane where only crocetin can 
quench its damaging activity. However, for E. coli, singlet oxygen produced by eosin-
(KLAKLAK)2 occurs in both solvent accessible and inaccessible regions, implying 
multiple binding sites and/or orientations for the conjugate.  
The superoxide quencher Tiron (10 mM) showed extensive protection for S. 
aureus, demonstrating a significant role for superoxide in the PDI mechanism for eosin-
(KLAKLAK)2. However, Tiron was toxic to E. coli. Tiron has been shown to chelate 
some metals,
93
 a known mechanism for disrupting LPS of Gram negative bacteria,
94
 
which is likely the cause of toxicity in this case. Although we cannot draw definite 
conclusions for the extent of damage caused to E. coli by superoxide, it is clear that 
superoxide is produced at high levels by eosin-(KLAKLAK)2 (Figure 3-4b), and is 
playing a significant role in the cell death of S. aureus (Figure 3-5a), which does not 
contain LPS. Since both Gram positive and negative strains share the structural features 
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of peptidoglycan and lipids as parts of their cell wall, it is likely then that superoxide 
also plays a role in the death of E.coli.  
To further establish that the PDI effects of eosin-(KLAKLAK)2 are primarily due 
to singlet oxygen and superoxide, we tested for the possible involvement of another 
ROS, the highly reactive hydroxyl radical (HO
•
), by using mannitol, a soluble HO
•
 
quencher (Figure 3-5). There was no protective effect of mannitol observed for either 
strain, although some toxicity was observed. Along with the extent of protection 
provided by quenchers of 
1
O2 and O2
•-
, this suggests that HO
•
 is not a significant 
contributor to the PDI activity of eosin-(KLAKLAK)2. Along with results from EM and 
in vitro assays, this data suggests that both 
1
O2 and O2
•-
 are significant contributors to the 
PDI activity of eosin-(KLAKLAK)2 at the membrane surface of bacteria. In particular, 
the quenching activity of crocetin, a lipid-soluble quencher, towards both strains 
suggests that the lipid bilayer is a common target of eosin-(KLAKLAK)2 activity 
between the two strains. 
 
3.2.4 Eosin-(KLAKLAK)2 shows greater levels of binding and leakage towards 
liposomes of bacterial lipid composition 
After results from EM and ROS-quenching experiments supported the lipid 
membrane as a target for eosin-(KLAKLAK)2 activity, we hypothesized that the 
particular membrane composition of bacteria might provide a basis for the preferential 
binding and activity that we observed previously for eosin-(KLAKLAK)2 towards 
bacteria over mammalian cells.
10
 Also, since eosin-(KLAKLAK)2 binds to and kills both 
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Gram positive and negative strains, it seemed reasonable to test a common component of 
the two membranes, namely, the lipids. To test this hypothesis, we performed LUV 
leakage assays using liposomes of different lipid composition to model the bacterial and 
mammalian lipid membranes. LUVs contained self-quenching concentrations of calcein 
(60 µM), allowing for detection of content leakage by the increase in calcein 
fluorescence after un-quenching. LUVs (200 µM total lipid) with or without eosin-
(KLAKLAK)2 present in solution (10 µM), were irradiated for 30 min under the same 
conditions as bacterial killing assays, after which, 0.1% Triton X-100 was added to 
determine the remaining fluorescent signal still encapsulated (shown at 31 min).  
Figure 3-6a shows that light alone or Eosin Y alone (10 µM) does not cause 
leakage for either type of LUV. On the other hand, eosin-(KLAKLAK)2 has only a slight 
effect on mammalian (Mam) LUVs, while bacterial (Bac) LUVs show early and 
continued leakage (Figure 3-6b). After the addition of Triton X-100, it is apparent that 
the total fluorescence of LUVs treated with eosin-(KLAKLAK)2 is significantly 
diminished compared to LUVs alone or with eosin Y, indicating significant bleaching of 
calcein caused by eosin-(KLAKLAK)2 during irradiation. This means that the apparent 
fluorescence of calcein throughout the irradiation process is actually underestimated for 
eosin-(KLAKLAK)2 in this assay, although this signal still provides us with a lower 
limit of leakage. The greater bleaching of calcein by eosin-(KLAKLAK)2 compared to 
eosin Y suggests a closer proximity to the membrane, or an enhancement of bleaching 
resulting from the altered ROS production for the conjugate, or both. The effect of both 
1
O2 and O2
•-
 quenchers for Bac LUVs with eosin-(KLAKLAK)2 was a reduction in 
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Figure 3-6: Eosin-(KLAKLAK)2 lyses LUVs of bacterial lipid composition, but not 
of mammalian composition. Eosin-(KLAKLAK)2 (10mM) with “Mammalian” (Mam) 
LUVs (50/30/20 PC/Chol/SM; 200mM total lipid) (a), and “Bacterial” (Bac) LUVs 
(75/20/5 PE/PG/CA; 200mM total lipid) (b). Samples were irradiated with the same 
conditions used for bacterial killing assays.  
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leakage (Figure 3-7), indicating a role for each of these ROS in lipid disruption. NaN3 
has a greater quenching effect than crocetin in this system, suggesting that the PS is 
solvent exposed.  
One interesting observation was the formation of precipitates seen at the earliest 
time points with Bac LUVs (indicated by arrows in magnified images), while 
precipitates do not form with Mam LUVs (Figure 3-8a). Investigation of these 
precipitates by fluorescence microscopy (Figure 3-8b) reveals extensive aggregates of 
LUVs, ranging broadly in size, with a typical aggregate pictured here at ~90 µm across. 
This distance corresponds to the width of roughly one thousand intact LUVs. While it is 
unclear what proportion of the aggregate contains intact LUVs, the fluorescence image 
shows fluorescence throughout the aggregate (sample had 10 min irradiation), which 
could be from either eosin-(KLAKLAK)2 or calcein in this case, since both are excited 
by the FITC filter cube used for imaging. While the presence of eosin-(KLAKLAK)2 in 
solution is significantly diminished after 10 min, the aggregates in the samples are 
clearly still pink in color, indicating the presence of eosin-(KLAKLAK)2 within the 
aggregates (since the LUV solutions are only pink after addition of eosin-
(KLAKLAK)2). It is unclear whether the apparent decrease of eosin-(KLAKLAK)2 in 
solution is only the result of co-precipitation with the LUV aggregates, or whether a 
significant bleaching of the PS may also be occurring. Nonetheless, taken together, these 
results suggest that the lipid composition of bacteria may provide a sufficient basis for 
the preferential targeting of eosin-(KLAKLAK)2 to bacteria over mammalian cells. In 
addition, the isolated lipid component is susceptible to lysis and aggregation in the 
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Figure 3-7: Effect of 
1
O2 and O2
•-
 quenchers on leakage of LUVs with bacterial lipid 
composition. The soluble O2
•-
 quencher Tiron, and the soluble 
1
O2 quencher NaN3 
inhibit leakage from Bac LUVs (two-tailed t-test, * = p <0.05, ** = p< 0.01, *** = p< 
0.001). 
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Figure 3-8: Eosin-(KLAKLAK)2 causes aggregation of LUVs with bacterial lipid 
composition, but not with mammalian lipid composition. Isolated wells depicted 
above demonstrate significant bleaching of eosin-(KLAKLAK)2 during irradiation with 
Bac LUVs, and the accompanying precipitates indicated by arrows (a). Bright field and 
fluorescence images of a typical precipitate from Bac LUVs after 10 min of irradiation 
(b). Scale bar = 10µm. 
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presence of eosin-(KLAKLAK)2 and light. 
 
3.2.5 The AMP component of the eosin-(KLAKLAK)2 conjugate actively 
participates in membrane lysis 
Although bacteria killing experiments have shown that eosin-(KLAKLAK)2 in the 
presence of light can kill bacteria efficiently below 1 µM, the peptide without the PS is 
inactive at these concentrations (Figure 2-1). Since the PS-AMP conjugate shows much 
greater activity than the PS alone, this implies that (KLAKLAK)2 at least plays a 
targeting role for the PS. Up to this point, however, it had been unclear whether 
(KLAKLAK)2 also participated in membrane lysis, and if so, to what extent. In order to 
assess the role of the peptide in the PDI process, we needed to uncouple 
photosensitization by the PS from the potential membrane disruption by the peptide. To 
achieve this, we co-incubated LUVs with unconjugated (KLAKLAK)2 and a  free 
photosensitizer, chlorin e6 (Ce6), which can bind and sensitize LUVs on its own in the 
light. The absorbance spectrum of Ce6 and the transmittance of the red filter used during 
irradiation are shown in Figure 3-9. Although absorbance of Ce6 is high at 400 nm, the 
peaks at ~655 and 705 nm likely dominate the absorbance of light in the experiment due 
to the transmittance of the red filter and the output of typical quartz-halogen lamps both 
being relatively low at shorter wavelengths (our lamp spectrum is limited to 500 nm, but 
resembles typical spectra from other quartz-halogen lamps).  
Figure 3-10a shows the percent leakage from Bac LUVs alone or with Ce6 (10 
µM) in the presence or absence of (KLAKLAK)2 after a 10 min irradiation. The leakage 
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Figure 3-9: Overlay of the absorbance spectrum of Ce6 and transmittance of the 
red filter used for irradiation of Ce6. Absorbance was determined at ~10 µM Ce6. 
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of LUVs in the presence of both the PS and AMP is significantly greater for each 
concentration of AMP tested. In order to determine whether the increase in leakage for 
samples with both Ce6 and (KLAKLAK)2 indicated an additive or synergistic effect, the 
potential synergy was calculated with the equation: Synergy = LCe6+K / (LCe6 + LK), 
where LCe6, LK, and LCe6+K, represent the percent leakage in the presence of Ce6 alone, 
(KLAKLAK)2 alone, and with co-incubation of Ce6 and (KLAKLAK)2, respectively. 
Where synergy exists, there should be greater leakage with co-incubation, than seen for 
the sum of the two molecules alone, resulting in a value greater than 1. The results of the 
calculation for each concentration of (KLAKLAK)2 are shown in Figure 3-10b. Under 
these conditions, the addition of (KLAKLAK)2 results in a synergistic response for 
vesicle leakage, which increases with peptide concentration for the range tested.  
While the above results were suggestive of a synergistic enhancement of leakage 
by (KLAKLAK)2, we thought the enhanced leakage could possibly be due to a 
recruitment of greater amounts of the negatively charged Ce6 by the positively charged 
(KLAKLAK)2 to the lipid membrane. To ensure that oxidation of lipids could facilitate 
disruption by (KLAKLAK)2, we used H2O2 as an oxidizing agent to mimic the 
photooxidative damage caused by a PS. Using the same LUVs as the prior experiment, 
leakage was monitored during a pre-oxidation step with H2O2 and after addition of 
(KLALKAK)2 or a blank. The resulting leakage and synergy calculations are shown in 
Figure 3-11.   
 
 
  
68 
 
 
 
 
 
Figure 3-10: (KLAKLAK)2 shows synergistic leakage activity towards LUVs of 
bacterial lipid composition when co-incubated with Ce6 in the presence of light. (a) 
Leakage of Bac LUVs in the presence of (KLAKLAK)2 alone (■), or with co-incubation 
of (KLAKLAK)2 and Ce6 (10 µM) (■) for 10 min with light. Significant differences for 
samples +/- Ce6 determined by two-tailed t-test, * = p < 0.05, ** = p < 0.01, *** = p < 
0.001. (b) Fold synergy of (KLAKLAK)2 activity calculated from leakage values in (a). 
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3.2.6 The retro-inverso (KLAKLAK)2 peptide and retro-inverso eosin-
(KLAKLAK)2 conjugate maintain similar LUV leakage activity 
Retro-inverso peptides possess amino acid enantiomers of the original peptide 
and a reversed amino acid sequence. These changes result in the same spatial orientation 
of the amino acid side chains, but with the N and C termini at opposite ends from the 
original peptide. The advantage of such constructs is that they often possess similar 
activity to the original peptide with decreased potential for degradation by proteases 
since D-amino acids are less susceptible to proteolytic degradation. It should be noted 
that a consequence of the N- and C-termini switching ends with respect to the sidechains 
in the retro inverso construct, is that the conjugation of the PS to the N-terminus also 
changes the relative position of the PS to the opposite end with respect to the original 
sequence. 
To test whether the retro-inverso construct of eosin-(KLAKLAK)2, called RI-
eosin-(KLAKLAK)2, might possess similar membrane disruption activity, we performed 
preliminary assays for comparison. The absorbance spectra of RI-eosin-(KLAKLAK)2 is 
shown in Figure 3-12, along with eosin Y, 5(6)-carboxy-eosin Y, and eosin-
(KLAKLAK)2 for comparison. The retro inverso construct shows the same spectral shift 
observed for eosin-(KLAKLAK)2. LUV leakage assays in Figure 3-13 show that RI-
eosin-(KLAKLAK)2 also has the same selectivity for LUVs of bacterial lipid 
composition as seen for the original peptide, with slightly more activity towards bacterial 
LUVs. Additionally, the peptide alone, RI-(KLAKLAK)2, showed a similar appearance 
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Figure 3-11: (KLAKLAK)2 shows synergistic leakage activity towards LUVs of 
bacterial lipid composition after pre-oxidation with H2O2. (a) Leakage of Bac LUVs 
in the presence of (KLAKLAK)2 alone (■), or with co-incubation of (KLAKLAK)2 and 
H2O2 (13%) (■). Significant differences for samples +/- H2O2 determined by two-tailed 
t-test, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. (b) Fold synergy of (KLAKLAK)2 
activity calculated from leakage values in (a). 
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Figure 3-12: The absorbance of RI-eosin-(KLAKLAK)2 is the same as eosin-
(KLAKLAK)2. RI-eosin-(KLAKLAK)2 shows the same shift observed relative to either 
of the free eosin Y molecules.  
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Figure 3-13: RI-eosin-(KLAKLAK)2 lyses LUVs of bacterial lipid composition, but 
not of mammalian lipid composition. (a) RI-eosin-(KLAKLAK)2 (10mM) with 
“Mammalian” (Mam) LUVs (50/30/20 PC/Chol/SM; 200mM total lipid), and (b) 
“Bacterial” (Bac) LUVs (75/20/5 PE/PG/CA; 200mM total lipid). Samples were 
irradiated with the same conditions used for bacterial killing assays. Data reproduced 
from Figure 3-6 for comparison with eosin-(KLAKLAK)2. 
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of synergy as seen for (KLAKLAK)2 when co-incubated with Ce6, towards bacterial 
LUVs (Figure 3-14). 
 
3.3 Discussion 
Since the widespread use of antibiotics, visualizing the effects of antibacterial agents by 
EM has been limited to observing morphological changes in cells. Recently, a significant 
progression in the field of AMPs was achieved when small helical A-AMPs were 
visualized with bacteria by TEM for the first time using immunogold labeling.
95
 While 
this approach to study AMPs was indeed novel, experimental conditions were not ideal. 
In particular, the concentration of AMP used was ~600 µM, 10-fold greater than the 
concentration required to kill 85% of the culture. Despite the high peptide concentration, 
few peptides were observed on the cell membrane or inside S. aureus, which is puzzling 
when membrane interaction is required in all reported cases for A-AMPs.
96
  The small 
number of peptides (gold labels) observed may be the result of incomplete labeling by 
the immunogold approach. Due to the vast difference in size between the peptides and a 
gold-labeled antibody, the immunolabel might not be able to gain access to locations that 
are accessible to a peptide within a cell.
17
 Fixation of the samples might further diminish 
the ability of the immunolabel to diffuse through the resulting matrix, in order reach the 
peptide.
17
 
An alternative approach to immunogold labeling, used in this study, is the DAB 
photooxidation reaction, first described by Deerinck et al. This method uses a chemical 
reaction with small molecules to create a localized osmiophilic polymer for enhanced  
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Figure 3-14: Co-incubation of Ce6 with RI-(KLAKLAK)2 shows similar leakage 
activity towards LUVs of bacterial lipid composition as observed for Ce6 and 
(KLAKLAK)2 in the presence of light. (a) Leakage of Bac LUVs in the presence of 
RI-(KLAKLAK)2 alone (■), or with co-incubation of RI-(KLAKLAK)2 and Ce6 (10 
µM) (■) for 10 min with light. Significant differences for samples +/- Ce6 determined by 
two-tailed t-test, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. (b) Fold synergy of 
(KLAKLAK)2 activity calculated from leakage values in (a). 
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contrast by EM.
9, 17, 97
 The minute size of the DAB monomer in comparison to an 
antibody should allow for a drastic increase in access to peptide locations, and thus 
maximize signal sensitivity. We therefore saw the DAB method as a superior approach 
to gain mechanistic insight into the interaction of an AMP with bacteria. TEM and 
STEM/EDS experiments show that eosin-(KLAKLAK)2 localizes to the cell membrane 
of bacteria in the dark, and upon irradiation, results in significant damage to cell 
membranes. The initial buildup of eosin-(KLAKLAK)2 upon membranes at sub-lethal 
concentrations in the dark is consistent with models for helical amphipathic AMPs in the 
literature.
62
  
While the DAB method might be suitable to distinguish individual proteins in 
biological samples,
9
 the small size of A-AMPs may not make it possible to quantify the 
number of peptides present. However, in the second S. aureus sample in Figure 3-2 (PS-
AMP, no light) many individual spots can be seen in high density, which may indicate 
an upper limit for detection of individual AMPs. Due to the chemical nature of DAB 
polymer formation by ROS, a short diffusion distance is possible, and could possibly 
result in the generation of more than one site of DAB polymer formation and staining by 
osmium tetroxide (OsO4), resulting in an overestimation of AMPs present. While the 
high density of spots remains consistent with membrane models for A-AMPs, an 
approach which can directly identify the presence of the peptide could more accurately 
depict the number and density of AMPs.  
Direct identification of eosin-(KLAKLAK)2 could be achieved by STEM/EDS, 
where positive identification is enabled by the presence of Br in the structure of eosin Y. 
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The localization of Br was isolated to the cell membrane and cellular debris, in 
agreement with the localization seen with the DAB method. This supports the use of 
DAB for visualization of small AMPs, and demonstrates the usefulness of STEM/EDS 
for direct identification of molecules containing an appropriate label for EDS detection 
within a biological sample. Current detection limits for STEM/EDS are around 0.5% of 
atomic presence in the sample. This may require relatively high local concentrations for 
molecules of interest, however, for AMPs which are expected to accumulate at the 
membrane surface, this may not be a significant issue, as shown in this work. DAB and 
STEM/EDS can be valuable for determining the location of AMPs or other molecules 
over time, which could lead to a better understanding of mechanisms for cellular 
penetration and intracellular localization.    
Although PS are most often characterized by their singlet oxygen generation in 
the literature, it is clear that eosin Y produces superoxide to a significant extent.
86
 The 
production of superoxide is surprisingly enhanced by conjugation of eosin Y to 
(KLAKLAK)2
 
(Figure 3-4), which suggests that superoxide could play an important role 
in PDI mechanisms. The first sign that (KLAKLAK)2 might alter the properties of eosin 
Y came from the red-shifted absorbance of eosin-(KLAKLAK)2 compared to either 
eosin Y or 5(6)-carboxy-eosin Y (Figure 2-2a). It may stand to reason then, that 
observation of shifted PS absorbance spectra should caution the user of potentially 
altered triplet state properties of the PS, and thus altered ROS production.  
The particular significance of superoxide in PDI is demonstrated in Figure 3-5a, 
where the superoxide quencher Tiron results in greater protection of S. aureus than any 
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other quencher tested. These results suggest that superoxide may actually be a more 
effective product for killing bacteria. While singlet oxygen has the advantage of a short 
lifetime which could limit non-specific damage, superoxide damage might also be 
sufficiently limited to reaction at its sight of production if it can be sufficiently targeted. 
Indeed, we previously showed that eosin-(KLAKLAK)2 in mixed cultures of RBCs and 
bacteria could cause a 3-log reduction of bacteria without lysis of RBCs, demonstrating 
sufficient restriction for ROS activity to bacterial cells, where the peptide was bound.
10
 
In the future it will be interesting to examine the relative efficiency of bacterial killing 
from targeted PS which generate primarily singlet oxygen or superoxide. 
Given the different membrane structures of Gram negative and positive bacteria, 
it is not surprising to see differing protection from quenchers, which may have differing 
degrees of access amongst the two membrane surfaces. DAB experiments with E. coli 
show that the majority of the peptide is bound at the outer membrane before irradiation, 
while S. aureus samples show a less restricted distribution, possibly indicating some 
degree of cellular penetration in the dark. Despite potential differences in binding sites, 
the PDI activity is similar for both strains, implying that the exact molecular binding 
targets may not be particularly important. The only importance may be that eosin-
(KLAKLAK)2 is in sufficient proximity to the surface, demonstrated by the fact that the 
soluble eosin Y alone has no PDI effect at even 10-fold the concentration of eosin-
(KLAKLAK)2 required to achieve a 5-log reduction in bacterial cultures. The attraction 
to bacterial cells over mammalian cells provided by (KLAKLAK)2 supports the use of 
short A-AMPs as targeting agents to achieve localized damaged with PS. A-AMPs may 
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hold a distinct advantage over previously used poly-lysine or arginine-rich peptides, 
which are known to also bind mammalian cells, thereby decreasing specificity.  
The attraction of AMPs to bacterial over mammalian membrane components 
may come from negatively charged LPS and peptidoglycan layers, as well as from lipids. 
However, AMPs must encounter and interact with a lipid layer at some point to achieve 
pore formation or passage through the membrane for their activity, and a lipid layer is 
common to both Gram types. Furthermore, PS-based strategies are known to act via lipid 
oxidation mechanisms. In this light, we examined whether the differences in lipid 
composition between mammalian cells and bacteria might be sufficient to explain 
differences in membrane disruption activity after treatment with eosin-(KLAKLAK)2. 
Leakage of encapsulated calcein from liposomes was clearly evident with a bacterial 
lipid composition, while little effects could be observed from the mammalian lipid 
counterparts (Figure 3-6), suggesting that the differences in lipid composition could 
indeed be sufficient for differences in lipid disruption during photodynamic processes. 
Another distinction of bacterial lipid membranes is the apparent bleaching of eosin-
(KLAKLAK)2 (Figure 3-8), which does not occur with mammalian LUVs. This could be 
indicative of increased self-bleaching from either higher peptide concentration at the 
membrane, or perhaps insertion of the PS into the membrane where oxygen is 
approximately four times more soluble. However, the fact that leakage from bacterial 
LUVs is only significantly inhibited with the soluble quenchers NaN3 and Tiron (Figure 
3-7), suggests that membrane insertion of the PS is not significant in this model system.  
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Leakage of Bac LUVs caused by eosin-(KLAKLAK)2 leads to massive 
aggregation that is not seen before irradiation (Figure 3-8). This suggests that peptide 
binding at the surface of LUVs is not sufficient to interact with other LUVs in solution 
to achieve aggregation, and thus the observed aggregation must be due to photodynamic 
effects. These results imply a mechanism for the killing of bacteria, where lipid damage 
leads to disruption and aggregation of lipid components. While disruption and 
aggregation of Bac LUVs was clearly light dependent, we could not rule out a 
contribution from (KLAKLAK)2, which aside from targeting to bacteria, has its own 
antibacterial activity and may therefore participate in the lipid disruption. As seen in 
Figure 3-10, when (KLAKLAK)2 is uncoupled from the PS in the membrane (Ce6 was 
used here for its natural membrane affinity), the leakage in the presence of both PS and 
AMP is greater than PS alone in each condition. While a greater leakage might be 
expected, a synergistic effect is also observed from the presence of (KLAKLAK)2, 
indicating that (KLAKLAK)2 plays a significant role in the lipid disruption caused by PS 
activity. One weakness of this assay is that Ce6 has a negative charge, so it is possible 
that the presence of (KLAKLAK)2 at the membrane could actually recruit larger 
amounts of Ce6 to the membrane than would otherwise be present. In Figure 3-11 we 
addressed this issue by oxidizing LUVs in a manner independent of a PS, namely, pre-
treatment of LUVs with H2O2 before addition of (KLAKLAK)2. This assay also showed 
the same synergistic activity from the peptide, suggesting that the results from co-
incubation with Ce6 did, in fact, reflect synergy from the peptide. It is unclear from this 
data, however, whether additional Ce6 may have also been recruited to the membrane by 
  
80 
 
(KLAKLAK)2. From these results we can infer that similar peptide synergy effects are 
likely to take place when (KLAKLAK)2 is directly connected to the PS, as is the case for 
the eosin-(KLAKLAK)2 conjugate. These results support a model where (KLAKLAK)2 
and eosin Y act in synergy for the disruption of lipid bilayers by combining 
photochemical and physical disruption mechanisms.  
In systems consisting of peptide reagents or components, retro inverso peptides 
can be synthesized to reduce the proteolytic degradation that occurs with the typical L-
amino acid peptides. The RI-eosin-(KLAKLAK)2 conjugate and RI-(KLAKLAK)2, 
respectively, showed  improved leakage toward bacterial LUVs (Figure 3-13) as well as 
an increase in apparent synergy with a PS (Figure 3-14). These data indicate that the RI-
eosin-(KLAKLAK)2 might be a better reagent for bacterial killing, although this remains 
to be tested. 
Overall, our results demonstrate that eosin-(KLAKLAK)2 is an effective 
antibacterial agent for PDI, which utilizes a synergistic interaction between PS and 
AMP. The properties of the PS are affected by conjugation, and may enhance the 
activity of the PS by altering ROS production. This design may serve as the basis for the 
future rational design of PS-AMP compounds with enhanced activity. The use of PS 
yielding greater levels of ROS, or AMPs with greater membrane disruption activity may 
provide for significant improvements in activity and bacterial specificity. The use of 
eosin Y as a dual marker for determining the location of AMPs or other small peptides in 
a biological context with the DAB method and STEM/EDS is also demonstrated in this 
work. One might envision of course, that the DAB and STEM/EDS approaches might be 
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separated, requiring only a PS for the DAB approach, or only a unique atomic label for 
STEM/EDS. We anticipate that the STEM/EDS approach may be of particular use for 
peptidomimetics, which often include atoms such as fluorine, which have little presence 
(background signal) in biological environments. In this case fluorine could serve as an 
intrinsic label, not requiring further modification of the molecule. While we have 
demonstrated these principles here, further tests are needed to validate these ideas.  
 
3.4 Materials and methods 
3.4.1 Materials 
Fmoc amino acids and HBTU were purchased from Novabiochem, while all 
solvents and chemicals were purchase from Sigma. One exception was 5(6)-carboxy 
eosin Y, which was purchased from Marker Gene Technologies. Lipids and cholesterol 
were purchased from Avanti Lipids.  
 
3.4.2 Solid phase peptide synthesis 
Same as in section 2, except retro-inverso (KLAKLAK)2 was synthesized using 
D-amino acids, which were also ordered from Novabiochem.  
 
3.4.3 Spectroscopy 
Same as in section 2, except Ce6 was used at 10 µM.  
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3.4.4 Light source for photodynamic experiments 
Same as in section 2.  
 
3.4.5 Photooxidation, fixation, and DAB polymerization in bacteria samples 
Samples of E. coli or S. aureus were prepared in the same manner used 
previously for phototoxicity experiments.
10
 Cultures were grown overnight in LB broth 
and fresh subcultures were prepared in the morning. After growth to O.D.600 ~0.6, the 
cells were pelleted and resuspended in phosphate buffer (100 mM NaCl, 10 mM 
Na2HPO4, pH 7.4 ), and this wash procedure repeated once more. The stock suspension 
was diluted to an O.D. which gave approximately 10
8
 CFU/ml for each strain. Eosin-
(KLAKLAK)2 (22 µl of 10µM), or water as a blank, was added to wells of a 96 well 
plate before addition of 200 µl of bacteria suspension in phosphate buffer (10
8
 CFU/ml). 
Samples were then kept in the dark for 2 min or illuminated under the halogen lamp 
assembly mentioned above for 2 or 5 min. Acrolein (100 µl of 2% solution) was then 
added to samples and incubated at room temperature for 20 min to fix the bacteria and 
any bound eosin-(KLAKLAK)2. To remove unbound eosin-(KLAKLAK)2, the samples 
were transferred to microcentrifuge tubes and pelleted in a small benchtop centrifuge for 
5 min. The supernatant was removed and samples were washed twice with 100 µl of 
cold 0.1 M cacodylate buffer. The pellets were then resuspended in the same buffer 
supplemented with 0.1 M glycine to react with any remaining acrolein in solution, and 
allowed to incubate for 20 min before addition of 100 µl of diaminobenzidine (DAB) 
buffer (1 mg/ml DAB in cacodylate buffer). These suspensions were transferred to a 96 
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well plate for 15min illumination to polymerize DAB specifically in the locations where 
the peptide was fixed, followed by an additional 100 µl of DAB buffer and 15 min of 
illumination. Samples were then transferred back to microcentrifuge tubes and washed 
twice with cacodylate buffer, followed by suspension in cacodylate buffer containing 1% 
(wt/vol) osmium tetroxide.  
 
3.4.6 Electron microscopy sample preparation and imaging 
After suspension of cells in osmium tetroxide, samples were dehydrated with 
10% steps of methanol to (10%-100%), infiltrated overnight, and embedded in Quetol 
651-Spurr epoxy resin
98
 and polymerized overnight.  Thin sections (200-250 nm) were 
cut with a Microstar diamond knife, (Huntsville, TX) using an AO Ultracut 
ultramicrotome picked up on grids and examined in a FEI Tecnai Field emission electron 
microscope at 200 kV accelerating voltage after carbon stabilizing the grids with 
approximately 10 nm of carbon using a Cressington 308 evaporative coater.  Elemental 
analysis was performed on a TECNAI F20 (scanning) transmission electron microscope 
(TEM/STEM) fitted with a Schottky field emission gun, a high angle annular dark field 
(HAADF) detector, and an EDAX instrument ultrathin window energy dispersive X-ray 
spectroscopy (EDS) detector. The combination of STEM and EDS allows direct imaging 
of a nanoscale area and in situ identification of component elements. An EDS spectrum 
at each spot in the area of interest was collected at a 200 kV accelerating voltage and a 
∼15° tilting angle with a stationary electron probe in STEM mode. An elemental map 
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was then acquired after choosing a proper energy window for an element-specific 
transition along with STEM-HAADF images. 
 
3.4.7 In vitro detection of singlet oxygen and superoxide production 
Detection of singlet oxygen from eosin Y or eosin-(KLAKLAK)2 was achieved 
by irradiation in the presence of imidazole and RNO (p-nitrosodimethylaniline).
89
 
Production of singlet oxygen from eosin Y leads to reaction with imidazole to form a 
peroxide intermediate, which subsequently reacts with RNO to cause bleaching of RNO 
absorbance. A total reaction volume of 200 µl was obtained by addition of 20 µl each of 
10X solutions for RNO, imidazole, quencher (or H2O blank), PS or PS-AMP (or H2O 
blank), and 120 µl phosphate buffer (10 mM phosphate, pH 7.4, 100mM NaCl). Final 
concentrations were 50 µM RNO, 8 mM imidazole, 100 mM sodium azide, and eosin Y 
or eosin-(KLAKLAK)2 at 1 or 10 µM. Illumination was carried out in the same manner 
as bacterial killing experiments to ensure relevant results. Bleaching of RNO was 
detected at 450nm using a Glomax Multi + Plate reader.  
Detection of superoxide was achieved by excitation of eosin Y and eosin-
(KLAKLAK)2 in the presence of NADH and NBT (nitro blue tetrazolium). A total 
reaction volume was obtained with 10X stock solutions in the manner mentioned above 
for the RNO assay. Final concentrations for eosin Y or eosin-(KLAKLAK)2 were 1 or 10 
µM, 10mM NADH, and 80 µM NBT. Illumination was carried out in the same manner 
as bacterial killing experiments. Reduction of NBT resulting in the production of a 
formazan was detected by absorbance at 600nm using a plate reader.  Since the RNO 
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and NBT reactions proceed by oxidation and reduction, respectively, there is no cross 
talk between the assays.
37, 91
 
 
3.4.8 Bacterial killing experiments with ROS quenchers 
Bacterial killing experiments were carried out in the same manner as described in 
section II, but using 11 µl of 20X quencher and 11 µl of 20X eosin-(KLAKLAK)2, 
before addition of 200 µl of 10
8
 CFU/ml bacteria culture. Crocetin was used from a 
100X in DMSO, requiring only 2.2 µl of stock in a total volume of 222 µl.  
 
3.4.9 Liposomes 
Large unilamellar vesicles (LUVs) of two compositions were prepared to 
represent lipids of bacterial
99
 and mammalian membranes. The mammalian composition 
was 50/30/20 of PC/Chol/SM, (PC = 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine; 
Chol = cholesterol, SM = choline sphingomyelin from stearic acid). The bacterial 
composition was 75/20/5 of PE/PG/CA (PE = dioleoyl-phosphatidyl ethanolamine, PG = 
L-α-Phosphatidyl-DL-Glycerol from chicken egg, CA = cardiolipin). Stock lipids in 
chloroform were mixed in a scintillation vial for the required molar ratios and the 
solvent evaporated under a nitrogen stream. These lipid mixtures were placed in a 
vacuum desiccator for a minimum of 2 hrs. before addition of swelling buffer. The lipids 
were then put through ten freeze-thaw cycles between liquid nitrogen and a water bath at 
42
o
C to obtain multi-lamellar vesicles (MLVs). These MLVs were extruded twenty one 
times using an Avanti extruder with a 100 nm polycarbonate membrane. For leakage 
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studies LUVs were prepared with a swelling buffer of 60 mM calcein in phosphate 
buffer (10 mM NaH2PO4, 100 mM NaCl, pH 7.4). After extrusion the free dye was 
excluded by running the LUVs through a Sephadex G-50 column in phosphate buffer. 
The calcein-loaded LUV preparations for both lipid compositions used for this 
manuscript were stable for approximately three weeks when kept at 4
o
C. This stability 
varies with lipid composition, however, and should be carefully noted in each case. We 
monitored stability over time by measuring the increase in fluorescence after addition of 
0.1% Triton X-100 (final concentration), using a 200 µl sample of 200 µM total lipid. 
Samples were placed in a 96 well plate and fluorescence determined with a Promega
®
 
Glomax Multi
®
 microplate reader. Ten-fold dilutions were made where needed to ensure 
that no self-quenching remained in the detergent samples, allowing for a linear 
comparison between samples. 
 
3.4.10 Leakage assays 
For leakage experiments, stock solutions of calcein-loaded LUVs were diluted as 
needed in phosphate buffer to obtain working solutions of 200 µM total lipid. Wells of a 
96 well plate were first filled with 11 µl of 20X quencher or H2O blank, followed by 11 
µl of 20X eosin-(KLAKLAK)2, RI-eosin-(KLAKLAK)2, or H2O blank. A volume of 200 
µl of the 200 µM LUV working solution was then added to each well. This mixture 
provides a 1X concentration of quencher and eosin-(KLAKLAK)2 or RI-eosin-
(KLAKLAK)2 with 90% of the total lipid concentration in the final solution. Samples 
were irradiated using the light source described above, and calcein release was 
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monitored by fluorescence with the plate reader (Ex 490, Em 510-570). Readings of all 
samples were taken before irradiation for a value at “0 min.” An estimate of fluorescence 
for 100% lysis was obtained by addition of 10X Triton X-100 (0.1% final concentration) 
to each sample after the last time point. For experiments examining the influence of 
membrane oxidation upon the activity of free (KLAKLAK)2 or RI-(KLAKLAK)2, LUVs 
were co-treated with 10 µM Ce6 and varying concentrations of (KLAKLAK)2 or RI-
(KLAKLAK)2. Alternatively, LUVs were pre-treated with H2O2 for 15 min before 
addition of free (KLAKLAK)2.  
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4. CONCLUSION 
 
Due to the unique broad-spectrum targeting of bacteria preferentially over 
mammalian cells, I propose that the eosin-(KLAKLAK)2 conjugate can serve as an 
effective antibacterial agent for PDI, as well as a model platform for the enhancement of 
PS by conjugation to AMPs, and vice versa. In section 2, I showed that conjugation of 
the soluble PS, eosin Y, to the AMP, (KLAKLAK)2, resulted in the targeting of eosin Y 
to bacterial membranes, even in mixed RBC and bacteria cultures. Furthermore, the 
eosin-(KLAKLAK)2 conjugate could achieve a 5-log reduction in both E. coli and S. 
aureus cultures under conditions showing no toxicity to RBCs or mammalian cell lines. 
Intriguingly, when eosin Y and eosin-(KLAKLAK)2 were bound to bacterial cells to the 
same extent (requiring 10-fold excess of eosin Y), eosin-(KLAKLAK)2 was toxic to 
bacteria, while eosin Y was not, suggesting a role for (KLAKLAK)2 beyond simple 
targeting. To address these observations, in section 3, I tested the respective roles for 
eosin Y and (KLAKLAK)2 in the conjugate. DAB and STEM/EDS methods, which have 
never been used for AMPs before, revealed a localization of eosin-(KLAKLAK)2 at the 
membrane before irradiation, and expanding to extracellular debris after irradiation, 
accompanied by alteration of membrane morphology and lysis. It was shown that eosin-
(KLAKLAK)2 demonstrates a strong preference for disruption of liposomes with 
bacterial lipid composition, resulting in significant leakage and aggregation, and 
suggesting a plausible cause of preferential attraction for bacterial over mammalian 
cells. A synergistic affect was revealed for both (KLAKLAK)2 and RI-(KLAKLAK)2 in 
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the presence of a PS for lipid membrane disruption, demonstrating that the nature of the 
peptide chosen for targeting a PS may be able to significantly enhance any damage 
achieved by the PS alone. Overall, the use of biochemical and microscopy techniques 
with mammalian cell lines, RBCs, and bacterial cells, has led to a mechanistic 
understanding of eosin-(KLAKLAK)2 in PDI. The results here have established the PS-
AMP approach as a working platform for PDI and may serve as the basis for the rational 
design of future PDI agents.  
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